Stockwinners Market Radar for February 21, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

22:01 EST Howmet Aerospace CFO sells $4.79M in common stock - In a regulatory filing, Howmet Aerospace disclosed that its CFO Ken Giacobbe sold 111.2K shares of common stock on February 16th in a total transaction size of $4.79M.

21:57 EST R1 RCM CEO buys $1.0M in common stock - In a regulatory filing, R1 RCM disclosed that its CEO Lee Rivas bought 71.8K shares of common stock on February 21 in a total transaction size of $1.0M.

21:13 EST EnLink Midstream CFO sells $4.5M in common stock - In a regulatory filing, EnLink Midstream disclosed that its CFO Benjamin Lamb sold 390K shares of common stock on February 17th in a total transaction size of $4.5M.

20:04 EST Cathie Wood's ARK Investment bought 129K shares of Recursion Pharmaceuticals

20:03 EST Cathie Wood's ARK Investment bought 56.9K shares of UiPath today

19:40 EST Mitek Systems discloses listing non-compliance notice from Nasdaq - Mitek Systems "reported that it received a notice on February 16, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market LLC advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the "Rule") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2022 in a timely manner and because the Company remains delinquent in filing its Form 10-K for the year ended September 30, 2022.

18:49 EST Palo Alto Networks CEO: We're delivering on the plan we set 12 months ago - In an interview on CNBC's Mad Money, Nikesh Arora said Palo Alto Networks has improved operating margins 440 bps from a year ago. It's three years ahead of guidance on operating margin, he noted. Cloud and Ai are "big opportunities" for the company.

18:37 EST Walmart CEO: Working with suppliers to get inflation down as soon as possible - In an interview on CNBC's Mad Money, Doug McMillon said Walmart's inventories are in good shape and the company has momentum going into 2023. "We have made changes to attract all ages and all income levels," he noted.

18:00 EST Sorrento Therapeutics approved for $75M in financing in chapter 11 case - Sorrento Therapeutics (SRNE) announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75M debtor-in-possession financing from JMB Capital Partners, in connection with Sorrento's chapter 11 case, which was filed on February 13. The financing will provide Sorrento with immediate liquidity so that it can continue operating its business as usual during its chapter 11 case. A hearing for final approval of the financing is currently set for March 29. Dr. Henry Ji, Ph.D., Chairman and CEO of Sorrento, commented: "We are pleased to have received approval from the Court for this financing, which will ensure Sorrento has the liquidity and ability to continue normal business operations, including the payment of employee wages and benefits and post-petition vendor obligations. We will continue our important work of developing new and innovative therapies for patients struggling with cancer, intractable pain, infectious disease, and more." As of its chapter 11 filing, Sorrento had over approximately $1B in assets. However, due to the possibility of certain actions by a litigation creditor, Sorrento and its wholly-owned, non-operating subsidiary Scintilla Pharmaceuticals, sought chapter 11 relief to safeguard its business and ensure the continuation of business operations, while protecting and maximizing value for stakeholders. Scilex Holding Company (SCLX), which is majority-owned by Sorrento, is not a debtor in Sorrento's chapter 11 case. Scilex is continuing to operate its business as usual, focusing on growing revenues, offering innovative, non-opioid pain management products, and developing meaningfully differentiated programs that address significant unmet needs and lead to better health outcomes for the millions of acute and chronic pain patients.

17:42 EST Silgan Holdings raises dividend 12.5% to 18c per share - Silgan Holdings announced that based on its continued strong financial performance and business prospects its Board of Directors declared a 18c per share quarterly cash dividend on the company's common stock, payable on March 31, 2023 to the holders of record of the common stock of the company on March 17, 2023. This represents a 12.5% increase from last year in the company's quarterly cash dividend, which the company has increased every year since it began paying cash dividends in 2004.

17:36 EST Black Stone sees FY23 Mineral and royalty production 35MBoe/d-37MBoe/d - Sees FY23 DD&A in $/Boe $3.50-$3.75 vs. $3.53 in FY22. Black Stone expects royalty production to increase by approximately 5% in 2023 relative to FY22 levels, primarily due to increasing development pace in the Shelby Trough by Aethon in the area and continued development in the Austin Chalk. Working interest production is expected to decline in 2023 as a result of Black Stone's decision in 2017 to farm-out participation in its working interest opportunities. The Partnership expects general and administrative expenses to be slightly higher in 2023 as a result of inflationary costs and selective hires made to support Black Stone's ability to evaluate, market and manage its undeveloped acreage positions to potential operators.

17:27 EST Caesars expects sports betting, iGaming to be EBITDA positive this year - Says expects benefit from several capital investment properties in 2023. Says customers responded favorably to in-game parlay improvements and introduction of live scores. Says work is underway to create an improved iCasino product experience for customers. Says offers sports betting in 29 jurisdictions and plans to register in Massachusetts later this week. Says nearly breakeven in digital segment. Says expects both sports betting and and iGaming to be EBITDA positive this year. Says Las Vegas is off to exceedingly strong Q1. Says March is setting up to be one of the best months ever in Vegas. Comments taken from Q4 earnings conference call.

17:01 EST Lockheed Martin delivers first C-130J-30 tactical airlifter to IDAF - Lockheed Martin delivered the first of five C-130J-30 Super Hercules tactical airlifters to the Indonesian Air Force, or IDAF during a ceremony here today, commemorating a new era in Hercules operations for this longtime C-130 operator.

17:01 EST Amesite announces 1-for-12 reverse stock split - Amesite announced that it will effect a 1-for-12 reverse split of its common stock effective as of the open of business on February 22, 2023. Commencing with the opening of trading on the Nasdaq Capital Market on February 22, 2023, the company's common stock will trade on a post-split basis under the same symbol AMST. The reverse stock split was approved by the company's stockholders at the special meeting held on February 15, 2023, with the final ratio determined by the company's board of directors. As a result of the reverse stock split, the CUSIP number for the company's common stock will now be 031094204. As a result of the reverse stock split, every 12 shares of issued and outstanding common stock will be exchanged for 1 share of common stock, with any fractional shares being rounded up to the next higher whole share. Immediately after the reverse stock split becomes effective, the company will have approximately 2,533,359 shares of common stock issued and outstanding. The reverse stock split is primarily intended to bring the company into compliance with Nasdaq's minimum bid price requirement.

16:48 EST Nogin enters CaaS agreement with Susana Monaco - Nogin announced an agreement with Susana Monaco, a designer women's fashion brand, to plug into its Commerce-as-a-Service, or CaaS, growth platform. With CaaS, brands gain access to Intelligent Commerce technology, a fractional team of experts across essential functions and e-commerce expertise. Nogin's CaaS will allow Susana Monaco to retain all the benefits of having a smaller, more flexible team while operating like a much larger company. Purpose-built for brands selling direct-to-consumer and through online channel partners, Nogin's Intelligent Commerce solution embraces and extends Shopify Plus with enterprise-level technology and automatic updates. Nogin allows brands to stay on Shopify Plus and removes the need to ever replatform again. For Susana Monaco, this means the company can plug into Intelligent Commerce to gain market-leading ecommerce technology without all the cost, complexity, time and risk of moving to a legacy enterprise platform. In addition, Susana Monaco will benefit from the full-stack ecommerce solution's advanced proprietary modules, such as the Customer Data Platform, Marketing Automation and Marketplace Dropship - features that help enhance sales growth and improve profits. These features are key for small to mid-sized brands that want to retain the flexibility of a smaller team while taking advantage of the fractional experts offered by Nogin.

16:44 EST Enstar Group subsidiary signs LPT agreement with RACQ Insurance - Enstar Group announced that one of its wholly-owned subsidiaries has signed a Loss Portfolio Transfer, or LPT, agreement with RACQ Insurance Limited, or RACQ, to reinsure 80% of RACQ's motor vehicle Compulsory Third Party, or CTP, insurance liabilities, covering accident years 2021 and prior. Under the reinsurance, which is effective as of July 1, 2022, RACQ will cede net reserves of approximately A$360M, and Enstar's subsidiary will provide approximately A$200M of cover in excess of the ceded reserves. The transaction will complete upon receipt of regulatory approvals and satisfaction of various other closing conditions.

16:41 EST Viper Energy sees FY23 production 20-22 MBo/d

16:35 EST Vital Energy sees FY23 production 34-37 MBO/d - The company said, "The 2023 outlook reflects the Company's ongoing focus on capital discipline and maximizing Free Cash Flow. Vital Energy plans to invest $625 - $675 million in 2023, maintaining relatively flat year-over-year activity levels. The Company has estimated cost inflation of approximately 15% over 2022 averages... The Company's activities are expected to result in full-year 2023 oil production of 34.0 - 37.0 MBO/d and total production of 72.0 - 76.0 MBOE/d. Production expectations exclude volumes associated with the Company's recently announced acquisition of producing properties."

16:34 EST ProPetro 'encouraged' by early 2023 results - Mr. Schorlemer added, "As we proceed in 2023, we expect that demand for our services will remain robust. Thanks to the work undertaken in the fourth quarter to reposition and reprice our assets, we began 2023 strong. We believe our January performance is a strong baseline and expect to build upon that momentum as we move through the balance of 2023." Mr. Sledge concluded, "We are encouraged by our early 2023 results and the opportunities ahead for ProPetro. We continue to transition our fleet and remain disciplined with regard to capital deployment, both of which will allow us to advance our position as a leading completions-focused oilfield services company. At the same time, we are taking actions to ensure that ProPetro is positioned to meet head-on any broader industry headwinds that may arise. Moving forward, we are confident ProPetro is well-positioned to capitalize on a large and attractive market opportunity within the Permian Basin and drive enhanced returns for our shareholders in what we believe should be a multi-year up-cycle. We remain focused on the pillars of our strategy: optimizing our businesses, transitioning our fleet and executing strategic transactions to accelerate Free Cash Flow."

16:31 EST BlueLinx says specialty product daily sales volumes down about 15% in Q1-to-date - BlueLinx said: "Through the first seven weeks of the first quarter of 2023, specialty product gross margin was in the range of 18% to 19% with daily sales volumes down approximately 15% versus the prior year reflecting the challenging macro environment. Structural product gross margin was in the range of 10% to 11% with relatively consistent sales volumes when compared to last year. The company will continue to evaluate market pricing for wood-based commodities and adjust accordingly at the end of each period."

16:29 EST Palo Alto Networks jumps 7% to $178.89 after beat and raise quarter

16:29 EST Coinbase says 2022 trading volume grew to $830B - The company states: "Trading volume grew to $830 billion in 2022 from $193 billion in 2020. Subscription and services revenues grew over 17x to nearly $800 million in 2022 from less than $50 million in 2020."

16:27 EST Lam Research announces new executive appointments - Lam Research announced a series of changes to its management structure across operations, innovation, product groups and sales, which together are intended to further position the company to capitalize on strong future growth opportunities in the semiconductor industry. Effective March 1, new leadership appointments include Pat Lord moving into the newly created position of executive vice president and COO. Vahid Vahedi will take on the role of senior vice president and chief technology officer - succeeding Rick Gottscho, who begins a new executive leadership position at the company focused on the innovation ecosystem. In addition, Sesha Varadarajan will oversee the newly combined etch and deposition business unit, Global Products Group, and Neil Fernandes becomes senior vice president, global customer operations. Lord, Vahedi, Gottscho, Varadarajan and Fernandes will report directly to Tim Archer, president and CEO at Lam.

16:26 EST Coinbase says aiming toward improving 2023 adjusted EBITDA - The company states: "We are operating toward a goal of improving full-year 2023 Adjusted EBITDA in absolute dollar terms versus full-year 2022 and believe our recent cost reduction efforts help position us to do so. When Coinbase went public, our goal was to operate at roughly break even across each crypto cycle. We have evolved our approach and are now setting our sights on positioning the company to generate Adjusted EBITDA in all market conditions."

16:23 EST Metals Company enters strategic partnership with Low Carbon Royalties - TMC announced a strategic partnership with Low Carbon Royalties, or LCR, to finance the development and production of low-carbon fuels and energy transition metals. TMC and LCR have agreed to a purchase and sale agreement whereby LCR has acquired a 2% gross overriding royalty on any future revenue derived from TMC's NORI area in the Clarion Clipperton Zone of the Pacific Ocean. In consideration for the NORI Royalty, TMC received a 35% strategic equity interest in LCR and $5M cash. TMC will retain the right to repurchase up to 75% of the NORI Royalty at an agreed capped return, exercisable in two transactions, between the second and the tenth anniversary of the agreement. If both repurchase transactions are executed, LCR's remaining gross overriding royalty on the NORI project revenue will be 0.5%. The NORI Royalty has been added to the LCR portfolio that contains a 1.6% gross overriding royalty on a producing natural gas field in Latin America, providing exposure to a lower-carbon transition fuel aligned with government emissions reduction policies. LCR is committed to expanding its portfolio of assets to deliver a new source of funding to producers of low-carbon energy and energy transition metals while delivering the high shareholder returns typical of the revenue royalty business model.

16:21 EST Workiva reports Q4-end customers at 5,664, net increase of 1,349 - The company states: "Workiva had 5,664 customers as of December 31, 2022, including approximately 922 ParsePort ESEF customers, a net increase of 1,349 customers from December 31, 2021. As of December 31, 2022, Workiva's revenue retention rate was 97.8%, and the revenue retention rate including add-on revenue was 108.5%. Add-on revenue includes changes in both solutions and pricing for existing customers. As of December 31, 2022, Workiva had 1,345 customers with an annual contract value ("ACV") of more than $100,000, up 20% from 1,121 customers at December 31, 2021. Workiva had 718 customers with an ACV of more than $150,000, up 24% from 578 customers in the fourth quarter of 2021. Workiva had 236 customers with an ACV of more than $300,000, up 29% from 183 customers in the fourth quarter of 2021."

16:19 EST Realty Income to increase March dividend 2.4% - Sumit Roy, Realty Income's President and CEO, said, "Our diversified portfolio continues to demonstrate strength with occupancy ending the year at 99% and a rent recapture rate of 105.9% for the year. Our investment pipeline remains healthy as investment yields trend higher, our investment capacity is well-funded with approximately $850M of outstanding forward equity raised, and our confidence in the long-term outlook of our platform remains steadfast. To that end, we announced an increase to the March 2023 dividend of 2.4%, representing 3.2% growth over the year-ago period."

16:18 EST Workiva names Julie Iskow as CEO - Workiva "announced that Julie Iskow, current COO, has been appointed to succeed Marty Vanderploeg asCEO, effective April 1, 2023. Vanderploeg is stepping down as CEO, but will remain with the company in the role of Non-Executive Chair of the Board of Directors."

16:14 EST MP Materials, Sumitomo Corp to partner on rare earth supply in Japan - MP Materials (MP) and Sumitomo Corporation (SSUMY) "announced an agreement to diversify and strengthen rare earth supplies in Japan. Under the agreement, SC will serve as the exclusive distributor of NdPr oxide produced by MP Materials to Japanese customers. Further, the companies will collaborate on the supply of rare earth metals and other products."

16:10 EST Chesapeake sees FY23 CapEx $1.765B-$1.835B

16:08 EST Kaman to partner with Tawazun Council on manufacturing assembly facility - Kaman "announced that its subsidiary, Kaman Precision Products and the Tawazun Councilhave signed a Business Plan Approval Letter for Kaman EMEA, Inc. to establish a Height of Burst manufacturing and final assembly facility in collaboration with Remah International Group - Sole Proprietorship LLC at the Tawazun Industrial Park. The BPAL was signed today in the Tawazun Pavilion at the International Defense Exposition 2023 by H.E. Tarik Al Hosani, Chief Executive Officer, Tawazun Council, and Carroll Lane, President, Kaman Precision Products, Inc. The FireBurst System HOB technology for Laser Guided Bombs will be utilized under Kaman's planned joint venture with RIG and will serve multiple customers in the UAE and the region. The FireBurst System can be used with any Paveway II General Purpose bomb configuration (GBU-10, GBU-12, GBU-16, GBU-58). It is a low cost force multiplier, effectively engages multiple targets with a single weapon, and requires no specialized tools for installation. The installation can be achieved by conducting a quick forward adapter swap in the field. It is cost effective and provides increased options for weapons effects."

16:03 EST Fox Factory subsidiary signs definitive agreement to acquire Custom Wheel House - Fox Factory announced that its subsidiary signed a definitive agreement to acquire Custom Wheel House, or CWH, from Thompson Street Capital Partners and other sellers. The purchase price for the transaction, which is subject to customary adjustments, is based on an enterprise value of $131.6M and will be financed through a combination of cash on hand and borrowings from the company's line of credit. The transaction is expected to close late in the first quarter of 2023, subject to customary closing conditions, and to be accretive to the company's fiscal 2023 financial results. CWH, based out of Rancho Dominguez, California, designs, markets, and distributes high-performance wheels, performance off-road tires, and accessories. The family of brands includes their premier brand Method Race Wheels, along with Tensor Tire, and GMZ Race Products, which are geared towards the manufacturing and distribution of off-road performance products for automotive, truck, and utility vehicles. This acquisition is complementary to FOX's upfitting and lift kit business and further broadens its product offering in a growing segment of the automotive industry.

15:46 EST Meihua International Medical Tech Co Ltd trading halted, volatility trading pause

15:03 EST Gilead says new data from four collaborative HIV studies reported at CROI - Gilead Sciences announced results from four collaborative studies evaluating novel investigational combinations and strategies with the potential to target the HIV viral reservoir or enhance immune response to maintain virologic control in the absence of antiretroviral therapy, or ART, stating that these latest findings "represent an ongoing multi-pronged approach in Gilead's HIV cure research program." The data were presented at the Conference on Retroviruses and Opportunistic Infections, or CROI, 2023 in Seattle. "The insights generated by the studies presented at CROI this year are advancing scientific knowledge on potential paths to a cure for HIV and expanding global understanding of what role broadly neutralizing antibodies, vaccines, and immune modulators may play in the future of HIV for people living with the virus. Gilead will continue exploring novel combination strategies in our pursuit to help end the HIV epidemic for everyone, everywhere," said Devi SenGupta, Executive Director, HIV Clinical Development, Gilead Sciences.

14:43 EST Tyson Foods announces agreement to acquire Williams Sausage Company - Tyson Foods has signed an agreement to acquire Williams Sausage Company, Inc. of Union City, Tenn., both companies announced. Terms of the acquisition were not disclosed, and the transaction is still subject to approval by U.S. regulators. Williams Sausage Company employs approximately 500 team members and provides fresh and fully cooked sausage, bacon and sandwiches to retail and foodservice customers. "The addition of Williams Sausage Company aligns with our strategic intent of expanding our capacity to serve our customers. We also look forward to welcoming Williams' dedicated team members to the Tyson Foods family," said Stewart Glendinning, Group President, Prepared Foods for Tyson Foods.

13:54 EST Coliseum Capital files lawsuit to invalidate Purple Innovation preferred stock - Coliseum Capital Management, which identifies itself as the largest stockholder of Purple Innovation, owning approximately 44% of the common stock, announced that it has filed a lawsuit in the Delaware Court of Chancery to invalidate Purple's recently issued "Proportional Representation Preferred Linked Stock," which Coliseum believes deprives Purple stockholders of a fair and democratic election of directors at the Company's 2023 Annual Meeting. "The preferred stock - issued without the approval of Purple's stockholders and in direct response to Coliseum's nomination of directors to the Purple Board of Directors - violates the Company's charter, fundamentally transforms the "one share, one vote" structure used to elect Company directors into a cumulative voting regime that prevents holders of a majority of the common stock from electing or removing the full board, and is a bad faith attempt by the Special Committee of Purple's Board to entrench itself and thwart shareholder democracy. Specifically, the preferred stock issuance violates those provisions of the Company's charter that limit the form of stock distributions to holders of the Company's Class A shares to additional shares of Class A common stock," Coliseum stated.

13:31 EST Microsoft, Nvidia announce 'expansive' new gaming partnership - Microsoft (MSFT) and Nvidia (NVDA) announced the companies have agreed to a 10-year partnership to bring Xbox PC games to the Nvidia GeForce NOW cloud gaming service, which has more than 25 million members in over 100 countries. "The agreement will enable gamers to stream Xbox PC titles from GeForce NOW to PCs, macOS, Chromebooks, smartphones and other devices. It will also enable Activision Blizzard PC titles, such as Call of Duty, to be streamed on GeForce NOW after Microsoft's acquisition of Activision closes... The partnership delivers increased choice to gamers and resolves NVIDIA's concerns with Microsoft's acquisition of Activision Blizzard. NVIDIA therefore is offering its full support for regulatory approval of the acquisition. Microsoft and NVIDIA will begin work immediately to integrate Xbox PC games into GeForce NOW, so that GeForce NOW members can stream PC games they buy in the Windows Store, including third-party partner titles where the publisher has granted streaming rights to NVIDIA. Xbox PC games currently available in third-party stores like Steam or Epic Games Store will also be able to be streamed through GeForce NOW," Microsoft stated. "Xbox remains committed to giving people more choice and finding ways to expand how people play. This partnership will help grow NVIDIA's catalog of titles to include games like Call of Duty, while giving developers more ways to offer streaming games. We are excited to offer gamers more ways to play the games they love," said Microsoft Gaming CEO Phil Spencer.

12:57 EST 'Avatar: The Way of Water' now third highest-grossing film of all time over - Over the weekend, 20th Century Studios' and Lightstorm Entertainment Production's Avatar: The Way of Water-nominated for four Academy Awards, including Best Picture-became the third highest-grossing film of all time worldwide. With $2,243.2 million earned to date, the film passed Titanic with $2,242.8 million global to date. Globally after its 10th weekend, the film has grossed an estimated $657 million domestically and $1,586 million internationally. Avatar: The Way of Water has also passed Jurassic World to become the ninth highest-grossing film of all time domestically, Disney says. Director James Cameron has three of the top four highest-grossing global movies of all time, with Avatar at No. 1, Avatar: The Way of Water at No. 3, and Titanic at No. 4. Avatar: The Way of Water-which stars Sam Worthington, Zoe Saldana, Sigourney Weaver, Stephen Lang, and Kate Winslet-is also the highest-grossing film of all-time in France, Germany, Austria, Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lebanon, Lithuania, Norway, Portugal, Romania, Slovenia, Slovakia, Turkey, UAE, Cambodia, Mongolia, New Zealand, Colombia, and Puerto Rico. Reference Link

12:29 EST TC BioPharm Ltd (ADR) trading resumes

12:18 EST EPA requires Norfolk Southern to conduct all cleanup actions in Ohio - The Environmental Protection Agency ordered Norfolk Southern to conduct "all necessary actions" associated with the cleanup from the East Palestine, Ohio, train derailment. As part of EPA's legally binding order, Norfolk Southern will be required to: Identify and clean up contaminated soil and water resources; Reimburse EPA for cleaning services to be offered to residents and businesses to provide an additional layer of reassurance, which will be conducted by EPA staff and contractors; Attend and participate in public meetings at EPA's request and post information online; Pay for EPA's costs for work performed under this order. As part of the order, EPA will approve a workplan outlining all steps necessary to clean up the environmental damage caused by the derailment. "If the company fails to complete any actions as ordered by EPA, the Agency will immediately step in, conduct the necessary work, and then seek to compel Norfolk Southern to pay triple the cost," the agency said in a statement. "The Norfolk Southern train derailment has upended the lives of East Palestine families, and EPA's order will ensure the company is held accountable for jeopardizing the health and safety of this community," said EPA Administrator Michael Regan. "Let me be clear: Norfolk Southern will pay for cleaning up the mess they created and for the trauma they've inflicted on this community."

12:07 EST Amazon launches 'Integrated Private Wireless' with telco companies - Amazon Web Services (AMZN) announced an Integrated Private Wireless on AWS. Built with Deutsche Telekom (DTEGY), KDDI (KDDIY), Orange (ORAN), T-Mobile (TMUS), and Telefonica Tech, the Integrated Private Wireless program combines private 4G and 5G wireless technologies with AWS services across AWS Regions, AWS Local Zones, AWS Outposts, and AWS Snow Family, the company said in a blog post. Reference Link

12:00 EST Glatfelter falls -13.2% - Glatfelter is down -13.2%, or -54c to $3.50.

12:00 EST Donnelley Financial Solutions falls -21.0% - Donnelley Financial Solutions is down -21.0%, or -$10.43 to $39.14.

12:00 EST Helix Energy rises 15.5% - Helix Energy is up 15.5%, or $1.18 to $8.80.

11:30 EST Asensus Surgical trading resumes

11:16 EST Ford announces MoU with LG Energy and Koc for battery joint venture - Ford Motor, LG Energy Solution and Koc Holding announced that they have signed a non-binding memorandum of understanding, or MoU, to form a new joint venture subject to final agreement by all the parties to "create one of Europe's largest commercial electric vehicle battery cell facilities near Ankara, Turkey, strengthening the foundation for Ford's electric future in Europe." Ford said: "The new joint venture will be located in an organised industrial zone in Bakent, near Ankara. The project is on track and expected to break ground later this year. Production is intended to start in 2026 with the three parties committing to at least 25 GWh of annual production capacity, which could potentially expand up to 45 GWh." Reference Link

10:27 EST Cleveland-Cliffs announces price increase for hot rolled, cold rolled products - Cleveland-Cliffs announced that it is increasing current spot market base prices for all carbon hot rolled, cold rolled and coated steel products by a minimum of $100 per net ton, effective immediately with all new orders. Cliffs' minimum base price for hot rolled steel is now $1,000 per net ton.

10:03 EST Anika Therapeutics issues statement in response to Caligan Partners letter - Anika Therapeutics issued the following statement in response to the letter by Caligan Partners LP: "Over the last six months, members of Anika's Board of Directors and management have met with Caligan Partners eight times to better understand its views and discuss Anika's strategy, which we are confident will drive significant growth and value creation. Anika has made meaningful progress against our strategy to become a leader in joint preservation and restoration, one of the highest opportunity spaces in orthopedics. This strategy expands Anika's market opportunity from $1 billion to more than $8 billion. At the same time, we continue to build on our leadership position in osteoarthritis pain management, which generates positive cash flows and supports, among other things, the investments we are making in new products across regenerative, sports medicine and joint solutions to capitalize on our opportunity in joint preservation. Anika's Board and management team are confident that the continued successful execution of our strategy will drive significant shareholder value. With a strong balance sheet, a robust foundation of clinical data, a comprehensive portfolio across the joint preservation continuum of care and a regular cadence of new product launches planned for 2023 and beyond, we believe Anika is uniquely positioned for meaningful growth and value creation in the years ahead. Our Board and management team will continue to act in the best interests of the Company and all of our shareholders. Since June 1, 2022, Anika's stock price has increased by approximately 40% compared to the NASDAQ Composite Index, which decreased by approximately 2%."

10:00 EST CNH Industrial announces industrial cooperation agreement with Tobroco-Giant - CNH Industrial has signed an industrial cooperation agreement with Tobroco-Giant, a Netherlands-based construction equipment manufacturer that specializes in the development and manufacturing of compact construction equipment. The agreement will see Tobroco-Giant's compact and sub-compact wheel loaders distributed under CNH Industrial's CASE Construction Equipment and New Holland Construction brands in North America.

10:00 EST American Equity falls -12.4% - American Equity is down -12.4%, or -$5.58 to $39.41.

10:00 EST Jeld-Wen rises 16.5% - Jeld-Wen is up 16.5%, or $2.12 to $14.99.

10:00 EST Home Depot says seeing very good project demand - Says still in an inflationary environment, but it's abating. Expects continued improvement in supply chains in 2023. Says bullish on long term demand for home improvement. Sees pressure from lumber "predominantly" in 1H23 vs. 2H23. Says price sensitivity broader in Q4 vs. Q3, mainly in big ticket, discretionary items. Expects comps in 1H23 "slightly lower" than 2H23. Targeting flat gross margin for 2023.

09:47 EST X Financial falls -9.2% - X Financial is down -9.2%, or -31c to $3.06.

09:47 EST American Equity falls -12.1% - American Equity is down -12.1%, or -$5.45 to $39.54.

09:47 EST Manitowoc rises 12.8% - Manitowoc is up 12.8%, or $1.84 to $16.20.

09:46 EST Karyopharm, Menarini receive full Marketing Authorization for Nexpovio - Karyopharm Therapeutics and the Menarini Group announced that the United Kingdom's Medicines and Healthcare Products Regulatory Agency has granted full Marketing Authorization for Nexpovio in combination with once-weekly bortezomib and low-dose dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. With this approval extending Nexpovio's indication in Great Britain, the conditional marketing authorization is now converted to full approval, the company said in a statement. Stemline Therapeutics, a wholly owned subsidiary of the Menarini Group, will be responsible for all commercialization activities in the U.K.

09:39 EST Chesapeake Utilities announces plans for company's first RNG facility in Florida - FPU Renewables announced plans to construct, own and operate a dairy manure renewable natural gas, or RNG, facility at Full Circle Dairy in Madison County, Florida. FPU Renewables and its parent, Florida Public Utilities Company, are subsidiaries of Chesapeake Utilities Corporation. "The project will capture and clean methane from manure generated by cows, producing 100,000 average dekatherms of RNG annually. The project represents a capital investment of $22 million, with the first injection of RNG projected to occur in 2024. Chesapeake Utilities is evaluating further investment opportunities to bring the RNG produced at the facility to market. Additionally, several offtake options for the RNG are under consideration," the company stated.

09:35 EST Lantern Pharma trading resumes

09:34 EST Constellation Energy to invest $800M in new equipment at IL nuclear plants - Constellation said it will invest $800M in new equipment to increase the output of its Braidwood and Byron Generating Stations in Illinois by approximately 135 megawatts, enough to power the equivalent of 100,000 average homes around the clock every year. The additional always-on, carbon-free power generated will result in the equivalent of removing 171,000 gas-powered vehicles from the road per year, or the equivalent of adding 216 intermittent wind turbines to the grid, using Environmental Protection Agency data. The project is expected to create work for thousands of skilled union workers during construction while expanding economic activity for surrounding businesses in the plant communities. The additional jobs come on top of the 1,200 permanent workers at the two plants. "These investments in our world class nuclear fleet will allow us to generate more zero-carbon energy with the same amount of fuel and land, and that's a win for the economy, the environment and Illinois families and businesses who rely on our clean energy," said Joe Dominguez, president and CEO of Constellation.

09:30 EST Greenpro Capital's incubatee company catTHIS obtains S-1 effectiveness - Greenpro Capital announced that its incubator company, catTHIS Holdings Corp has obtained S-1 Notice of Effectiveness from the U.S. SEC on February 10, 2023. Greenpro Capital currently holds 2,000,000 shares in catTHIS.

09:30 EST Banxa Holdings in the process of completing audited annual financial statements - Banxa Holdings announces that it is in the process of completing its audited annual financial statements for the fiscal year ended June 30, 2022 and related management's discussion and analysis with the help of its auditors. The Company is dedicated to resolving the remaining audit items and submitting the necessary filings as soon as possible. Once completed, a news release will be issued to announce the submission of the Annual Filings and interim financial statements for the periods ended September 30, 2022 & December 31, 2022. Despite the challenges posed by current market conditions and the evolving regulatory landscape, Banxa's operations remain positive and stable. The delay in the Annual Filings and the prolonged audit is due to several factors, including: Banxa has conducted a comprehensive review and analysis of its transactions resulting in adjustments to its revenue recording methods for FY2022. This adjustment was made to ensure that revenue is being appropriately presented based on how a specific cryptocurrency interacts with a Banxa wallet which has an impact if revenue is treated as "Agency" or "Principal" revenue. As a result of this review, the Company will report approximately AUD$71m in revenue for the fiscal year ended June 30, 2022, an increase of 53% from AUD$46m the year prior. The revenue recording methods do not have any impact on the gross profit or bottom lineof the company but rather reflects a change in business process that ensures accurate reporting and compliance with regulatory requirements around accounting standards. Liquidity Providers: As part of its operations, Banxa sources liquidity from numerous global cryptocurrency exchanges known as Liquidity Providers. These exchanges are generally considered "un-regulated" from a regulatory perspective and are usually not SOC compliant which has required further audit procedures needed to be implemented to validate the accounting treatment of these digital assets held on these exchanges. The Company is pleased to report that it is close to completing this review and does not anticipate any impact on its financial statements. Reclassification of 'Deposits at Exchanges' to 'Receivables at Exchanges': Given the current state of the cryptocurrency markets and the risks associated with holding coins on third-party cryptocurrency exchanges, Banxa has had to reclassify its digital assets held on third-party exchanges from a 'Deposit' to a 'Receivable'. Both remain Current Assets and will not impact the Current Assets on the balance sheet. Significant growth: Banxa has achieved significant transaction volume of circa AUD$1.6 billio in FY2022 financial year and the Company remains in a growth stage as it continues to expand its operations and offerings. As part of this growth, management recognizes the need for continuing to improve internal processes and better support financial reporting requirements. The Company has now appointed its COO Sean Moynihan as interim-CFO while the search for a full time CFO continues.

09:28 EST FingerMotion announces results of annual meeting - FingerMotion announces that, in conjunction with the holding of the Company's recent annual meeting of stockholders on February 17, 2023, the following were the outcome of the matters voted on at the annual meeting: Hsien Loong Wong, Yew Poh Leong, Michael Chan and Eng Ho Ng were elected to the Board of Directors of the Company; Centurion ZD CPA & Co. was appointed as the Company's independent registered public accounting firm; the Company's 2023 Stock Incentive Plan was approved; the amendment to the exercise price of outstanding stock options from $8.00 to $3.84 was approved; the issuance in excess of 20% of the shares of the Company's common stock to the Company's primary lender upon repayment by conversion of the note and exercise of the warrant held by the primary lender was not approved; hthe lowering of the floor price under the note and warrant held by the Company's primary lender from $0.86 to $0.50 per share of the Company's common stock was not approved; the Company's executive compensation was approved; and the following executive officers of the Company were re-appointed by the Board of Directors of the Company immediately following the annual meeting: Martin Shen: President and Chief Executive Officer; andYew Hon Lee: Chief Financial Officer, Secretary and Treasurer.

09:25 EST Avantax reports FY22 newly recruited assets at $1.7B - Avantax continued its record-breaking recruiting results during the fourth quarter of 2022, contributing to full-year 2022 newly recruited assets of approximately $1.7B, an increase of approximately 79% over 2021. "Avantax is the destination for Tax and Financial Professionals who want to grow by offering the differentiated value of tax-advantaged wealth management, especially as clients increasingly grow frustrated by advisors offering limited services," said Tim Stewart, VP and Head of Business Development for Avantax. "Our recruits don't want to be anonymous cogs in their broker-dealer's machine. They're joining Avantax to be part of our community of like-minded, growth-oriented peers who collaborate and help elevate each other as they grow." During the fourth quarter, 66 independent Financial Professionals affiliated with Avantax, including Kenneth S. Hamada, CRPC, who transferred his practice to Avantax from Independent Financial Group, LLC. Hamada picked Avantax to continue growing his practice's assets and geographic presence with Avantax's support.

09:23 EST EzFill signs agreement with South Florida Motorsports - EzFill Holdings announced that it has entered into an agreement with South Florida Motorsports, SFM, the organizers of the Formula 1 Crypto.com Miami Grand Prix 2023 to provide mobile fuel services for the build-out and operations leading up to the Miami Grand Prix, scheduled for May 5-7, 2023. Mike McConnell, EzFill Chief Executive Officer, commented, "It is a tremendous privilege to be chosen to service an event with Formula 1's prestige and global footprint, and we are thrilled with the opportunity. The 2022 Miami Grand Prix was a huge undertaking, and the 2023 event is expected to be even grander. It will require an enormous number of both fixed and mobile assets that will need to be constantly fueled. The Miami Grand Prix is as high profile an event as one can get and we believe it will be a tremendous opportunity for EzFill to showcase its capabilities. We're excitedly looking forward to showing the City of Miami what we can do."

09:21 EST Lexaria Bioscience announces results from HYPER-H21-4 study - Lexaria Bioscience announce additional findings from its human clinical study HYPER-H21-4 demonstrating a potentially novel mechanism of action of its patented DehydraTECH-processed cannabidiol capsule formulation in reducing blood pressure. The Food and Drug Administration has laid out clear guidelines for sponsors who seek to develop new anti-hypertensive drugs, specifically defining the need for medications that offer complementary modes of action. Lexaria believes that its latest results, detailed below and already peer-reviewed and published in the respected journal, "Biomedicine and Pharmacotherapy", may support DehydraTECH-CBD qualification within these FDA guidelines. Lexaria previously announced that the primary efficacy and safety objectives of the Study were successfully achieved, with resting BP significantly reduced in hypertensive patients, and sustained over the full 5-weeks of dosing with zero serious adverse events being reported throughout the Study. Lexaria is aware of only a handful of other published research studies, mostly in young, healthy and normotensive volunteers, that have investigated whether a sustained decrease in resting BP is possible following multiple weeks of oral CBD dosing; none of which have been successful in achieving this. Ongoing analyses of the Study data have revealed modulation of a circulating compound called catestatin in the patients. Catestatin is a multifunctional peptide known to have inhibitory effects on the sympathetic nervous system in the pathophysiology of hypertension. These analyses revealed that administration of DehydraTECH-CBD resulted in a statistically significant reduction in average baseline serum catestatin concentrations of 13.50 ng/mL to just 9.65 ng/mL after 5 weeks of dosing, which is a large drop of 28.5%. There were no statistically significant reductions in catestatin concentrations in the placebo group. As previously reported, mean arterial pressure also dropped significantly by 4.26 +/- 1.26 mm/Hg following the 5-week period of DehydraTECH-CBD dosing and this reduction was not observed with placebo. The extent of change in catestatin serum levels showed a strong correlation with the reduction in blood pressure. Overall, these latest results from study HYPER-H21-4 imply that the antihypertensive effects of DehydraTECH-CBD may be explained, at least in part, by its interaction with the sympatho-chromaffin system via catestatin modulation. This suggests a potentially unique mechanistic benefit upon cardiovascular regulation with DehydraTECH-CBD treatment that has not previously been demonstrated, to our knowledge, with testing of CBD for blood pressure reduction. CBD is known to have a wide array of distinct effects upon cardiovascular regulation. These include effects upon blood vessel tone, vascular inflammation, blood pressure, and cardiac contractility. The mechanisms of these observations are complex and involves interaction with receptors other than cannabinoid receptors, including actions exerted through various naturally occurring mediator compounds in the body. There is a clear medical and market need for alternative anti-hypertensive therapies, especially in the case of patients with so-called resistant hypertension who fail to adequately control their high BP with combinations of existing medications. Of note, the decreases in BP evidenced in the Study were similar in both those hypertensive patients on standard of care BP medications and those who were untreated for their hypertension upon Study entry. Therefore, the current results indicate that Lexaria's DehydraTECH-CBD has the potential to offer complementary and additive BP reduction benefits on top of any degree of improvements the standard of care medications provided. This additive improvement of DehydraTECH-CBD as an adjunct therapy, perhaps related to its pronounced effectiveness in modulating catestatin levels, could become a significant value enhancer should it eventually enter the marketplace as an approved hypertension treatment. Additional study endpoint analyses as described in the complete study protocol are still underway and any relevant material findings will be reported upon as these findings become available.

09:18 EST Plug Power, Acciona Energia present Valle H2V Navarra project - Plug Power (PLUG) and ACCIONA Energia (ACXIF) have presented to the Government of Navarra their Valle H2V Navarra joint project to build an industrial-scale, green hydrogen production plant in Rocaforte, Sanguesa. The project, currently in the development stage, involves the construction of a 25MW electrolyzer on the land plots adjacent to the Sanguesa biomass plant. The electrolyzer will be powered by hybrid renewable energy produced at a photovoltaic plant and a wind farm, both newly built facilities that are currently under development. The plans of Plug and ACCIONA Energia entail a total associated investment of EUR 87M, and the creation of over 500 direct, indirect, and induced jobs during the construction of the plant.

09:17 EST Asana names Shannon Duffy CMO, Taychakhoonavudh as customer experience chief - Asana announced that Shannon Sullivan Duffy has been hired as the new Chief Marketing Officer CMO and Neeracha Taychakhoonavudh has been hired as the Head of Customer Experience, to help continue to drive enterprise growth. Neeracha Taychakhoonavudh, Head of Customer Experience at Asana ."Both Shannon and Neeracha bring impressive enterprise experience and proven track records delivering for customers and driving business growth," said Anne Raimondi, Chief Operating Officer and Head of Business at Asana. "At Asana, we have a people-centric leadership style which both Shannon and Neeracha exemplify. We're excited to see their combined impact on our enterprise focus in 2023 and beyond." Asana also welcomes Neeracha Taychakhoonavudh to the team as Head of Customer Experience, supporting the global business from Asana's headquarters. Ms. Taychakhoonavudh joins the team after thirteen years at Salesforce, her most recent role being Executive Vice President, Global Customer Success, after a long-established career within the tech industry, including positions at Oracle and smaller startups.

09:12 EST Home Depot says seeing traction in interconnected business - Says seeing progress in supply chain buildout. Says customers less price sensitive than expected given inflationary environment. Expects 2023 to be "a year of moderation" in home improvement. Comments taken from Q4 earnings conference call.

09:10 EST Capital Product announces successful delivery of LNG carrier 'Asterix I' - Capital Product Partners announced the successful delivery of the LNG carrier 'Asterix I'. The vessel was delivered on February 17, 2023 and has started her seven year employment with Hartree Partners Power & Gas Company Limited, who maintain an option to extend by an additional two years. The vessel acquisition was financed through a combination of a $12.0 million cash deposit advanced to Capital Maritime & Trading Corp in 2022, $184.0 million of debt drawn under a sale and leaseback transaction with CMB Financial Leasing and $34.0 million of cash at hand. The CMBFL lease has quarterly principal repayments of $2.2 million, a tenor of ten years and the option to repurchase the vessel at a predetermined price after the first anniversary of the arrangement, together with a purchase option of $96.5 million at the expiration of the lease in February 2033.

09:09 EST Sesen Bio announces Glass Lewis recommendation to vote for merger with Carisma - Sesen Bio announced that independent proxy advisory firm Glass, Lewis & Co. recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics, in advance of the company's upcoming special meeting of stockholders scheduled for March 2. In reaching its conclusion that stockholders should support all proposals, including the merger and the proposed reverse stock split, Glass Lewis noted in its February 17, 2023, report: "...we believe it is reasonable to conclude that the board has likely secured from Carisma the best terms reasonably available to the Company at this time." "Shareholders should understand that with the Company having halted development of Vicineum, and with the completion of the transaction contemplated under the Roche Asset Purchase Agreement, the Company is now effectively a publicly-traded cash shell. As a result, the primary components of the Company's value are now its public listing and its available cash." "We understand that for the purposes of the proposed merger, the Company is effectively being valued at a premium of $15 million (or approximately 21.4%) to its net cash contribution, which we believe is reasonable." "The proposed merger will allow shareholders to continue participating in the potential future upside of a combined company that will be focused on developing Carisma's proprietary cell therapy platform. Shareholders will also obtain some immediate liquidity via the special cash dividend, along with additional potential upside from the CVRs." "We agree with the board that it is in the best interest of the Company to reduce the number of shares of common stock outstanding and thereby attempt to proportionally raise the per share price of the Company's common stock. A higher stock price may help to increase investor interest, attract and retain employees and improve the Company's ability to raise additional capital through equity offerings." The recommendation from Glass Lewis follows the February 16 report from Institutional Shareholder Services, recommending that stockholders vote "FOR" all proposals. In addition to the positive recommendations of the two leading proxy advisory firms, several of Sesen Bio's largest stockholders that together beneficially own approximately 12.8% of Sesen Bio's outstanding common stock have committed to vote their shares for the merger with Carisma. The Sesen Bio board of directors unanimously recommends that stockholders vote "FOR" each of the proposals listed on the White proxy card enclosed with the previously mailed definitive proxy statement / prospectus. Stockholders are urged to vote their shares in advance of the Special Meeting. Stockholders can switch their vote at any time to vote "FOR" the merger. Only the latest-dated proxy counts.

09:08 EST Koil Energy to provide LNG energy services - Koil Energy Solutions announced the receipt of an order to provide services for an LNG project in the Gulf of Mexico. The first phase is for installation engineering services, with potential future scopes expected to include custom designed installation equipment, flowline transpooling services and later, a potential long-term service agreement in support of various offshore operations. While the initial phases of the project are expected to be executed within the first half of 2023, discussions are ongoing for a multi-year service agreement similar to existing agreements the company has with major oil and gas operators.

09:07 EST Greystone affiliates collaborate with Cushman & Wakefield - Greystone Affordable Development, Greystone Housing Impact Investors (GHI), and Cushman & Wakefield (CWK) created a "dream team outcome in a challenging market" on four recent affordable housing acquisition and rehabilitation development transactions in South Carolina totaling $118M. Working with a variety of multifamily investment sales advisors at Cushman & Wakefield, with which Greystone has a strategic joint venture, the teams collaborated on the acquisition and mortgage revenue bond, MRB, investments with two separate non-profit entities. Greystone Affordable Development, working with Opportunity South Carolina on three separate acquisitions as the developer of record, partnered with Rob Schultz of GHI to identify an acquisition financing solution via tax-exempt mortgage revenue bonds. On a fourth, separate $31 million transaction with Greenville Housing Fund, Greystone's Adam Lipkin originated a financing solution via GHI, where Greystone Affordable Development will also serve as developer. Cushman & Wakefield's John Phoenix, Austin Green, and Ricky Gore represented the sellers of all four properties.

09:05 EST Arcimoto to begin 2023 vehicle production for spring deliveries - Arcimoto announced that it will start 2023 vehicle production on FUV and Deliverator with plans for first deliveries beginning in March. Headlining the model year 2023 product update is the new steering system that will deliver improved handling and maneuverability at all speeds while reducing steering effort by more than 40% from prior models. Arcimoto ended Q4 2022 with the most successful quarter yet delivering 89 vehicles. In 2022, Arcimoto delivered 228 customer vehicles, which increased the total number of Arcimoto vehicles on the road to more than 500.

09:05 EST Safe Bulkers announces agreement for acquisition of one Japanese Kamsarmax - Safe Bulkers announced that it has entered into an agreement for the acquisition of a Japanese, 81,800 dwt, dry-bulk, Kamsarmax class vessel at an attractive price with a scheduled delivery date within the second quarter of 2025. The newbuild vessel is designed to meet the Phase 3 requirements of Energy Efficiency Design Index related to the reduction of greenhouse gas emissions as adopted by the International Maritime Organization, and also comply with the latest NOx emissions regulation, NOx-Tier III. Including this agreement and following the delivery of MV Climate Ethics, our third newbuild in January 2023, the Company has an outstanding orderbook of nine newbuild vessels, with scheduled deliveries four in 2023, three in 2024 and two in 2025, of which one is Post-Panamax class and eight are Kamsarmax class vessels

09:03 EST STMicroelectronics expands STM32 family of advanced microcontrollers - STMicroelectronics has expanded its STM32 family of advanced microcontrollers with extra STM32U5 devices that raise performance while squeezing power consumption for longer runtimes and energy efficiency. The STM32U5 has also received NIST embedded random-number entropy source certification1; the industry's first to receive this endorsement. The new MCUs extend the range of code and data storage to 128Kbyte Flash for cost-sensitive applications, while also adding high-density versions for complex applications and sophisticated smartphone-like user interfaces. Among these, the STM32U59x/5Ax with 4Mbyte Flash and 2.5Mbyte SRAM has the largest on-chip memory of any STM32 MCU to date.

09:02 EST CME Group to launch Micro E-mini S&P 400, S&P 600 futures on March 20 - CME Group announced it will launch Micro E-mini S&P MidCap 400 and Micro E-mini S&P SmallCap 600 futures on March 20, pending regulatory review. These new contracts will complement the existing E-mini S&P MidCap 400 and E-mini S&P SmallCap 600 futures.

09:01 EST Allego commissions 4 EV fast-charging hubs on VINCI Autoroutes network - "Committed to supporting the development of low-carbon mobility, VINCI Autoroutes continues to deploy electric vehicle fast-charging hubs on its network. ... to accommodate those who will take to the road in France, VINCI Autoroutes welcomes 4 new fast-charging hubs, designed, deployed and managed by charge-point operator Allego . The hubs are located at Brouzils and Chavagnes , Rouille Pamproux , and Toulouse Sud Nord. In total, Allego has installed 16 ultra-fast chargers equipped with 32 charge points at these 4 locations. Each ultra-fast charger will dispense op to 300 kW. These locations will significantly reinforce existing infrastructure and enable EV drivers using the VINCI Autoroutes network to recharge up to 300 km range within 10 to 15 minutes. Each hub will also be equipped with two 50 kW charge points to ensure all electric vehicles currently in circulation can recharge at the hubs," said the company in part in a statement.

08:57 EST NV5 Global acquires Diversified Consulting Solutions, terms not disclosed - NV5 Global announced that it has acquired Diversified Consulting Solutions, a provider of owner representation services in the Mountain West Region. The acquisition was made with a combination of cash and stock and will be immediately accretive to earnings. Headquartered in Denver, Colorado, DCS specializes in owner representation consulting for municipalities and the K-12 and higher education markets. DCS oversees projects on an owner's behalf from concept through construction and final delivery. Services delivered by DCS include scheduling, vendor selection and payment, percent of completion calculation, and quality assurance.

08:55 EST Prosperity withdraws proposal to acquire American Equity - Prosperity Group Holdings issued the following statement, regarding its proposal to acquire the common shares of American Equity Investment Life Holding Company: "Prosperity is withdrawing its proposal to acquire American Equity for $45.00 per share. Given American Equity's refusal to engage and our desire to proceed only on a constructive basis, Prosperity has no interest in continuing to pursue our proposed transaction at this time."

08:53 EST Innodata says PR agencies, departments 'rapidly adopting' PR CoPilot - The company said, "Innodata announced that public relations agencies and departments are rapidly adopting PR CoPilot and providing glowing feedback about how it benefits their businesses. Innodata launched PR CoPilot last month as a module within its Agility PR platform."

08:50 EST PulpoAR announces Fingernail Segmentation, Skin Diagnostics integration - The Glimpse Group announced that its subsidiary company, PulpoAR, has integrated internally developed core Artificial intelligence based real time Fingernail Segmentation and Skin Diagnostics into its SaaS-based Augmented Reality products, including those expected to be utilized by a leading global social media company. The integration of these internally developed AI capabilities further solidifies PulpoAR's position as one of the leading global providers for virtual try-on offerings in the Beauty and Fashion industry segments, now covering the categories of makeup, nail polishing, skincare, glasses and hats.

08:49 EST Jaguar Health reaches 75% enrollement in Phase 3 OnTarget trial of crofelemer - Jaguar Health announced that patient enrollment has reached approximately 75% in the Company's pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy, with or without chemotherapy. Target trial enrollment of 256 patients is expected to complete in the second quarter of 2023.

08:47 EST Manulife Financial receives approval for normal course issue bid - Manulife Financial has received approval from the Toronto Stock Exchange for its normal course issuer bid permitting the purchase for cancellation of up to 55.7 million of its common shares, representing approximately 3% of Manulife's issued and outstanding common shares. As at February 13, 2023, Manulife had 1,858,214,865 common shares issued and outstanding. Under the NCIB, Manulife may purchase up to 1,689,515 of its common shares on the TSX during any trading day, which represents 25% of the average daily trading volume of 6,758,060 common shares on the TSX for the six months ended January 31. Purchases under the NCIB may commence through the TSX on February 23, 2023 and continue until February 22, 2024, when the NCIB expires, or such earlier date as Manulife completes its purchases. The total number of common shares repurchased under the NCIB and all other potential arrangements will not exceed 55.7 million common shares.

08:45 EST Yield10 Bioscience announces key advancements for enabling weed control - Yield10 Bioscience announced key advancements for enabling weed control for Camelina cultivation and for supporting grower adoption of this crop for the biofuel feedstock oil market. "Our team has made substantial progress developing elite herbicide tolerant spring and winter Camelina varieties," said Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience. "The results of our Southern U.S. winter field trials with the single HT trait in our spring Camelina lines as well as recent greenhouse studies on our next generation stacked HT trait package, which includes broadleaf weed control and tolerance to group 2 herbicide soil residues, indicate we remain on track to launch herbicide tolerant Camelina varieties. Our goal is robust weed control enabling growers to plant with confidence on a large scale. In 2023, we look forward to conducting further field testing and seed scale-up activities for our commercial quality HT lines, advancing development of our stacked herbicide tolerant lines, and accelerating our regulatory efforts in support of commercial launch of these important Camelina varieties to supply low-carbon intensity feedstock oil to the biofuels market."

08:45 EST Trust Stamp announces Notice of Allowance for latest patent application - Trust Stamp announces that it has received a Notice of Allowance for its latest patent application #17/230,684 by the United States Patent Office. The '684 application is directed to Trust Stamp's innovative processes for irreversibly transforming biometric and other identity data into an irreversibly transformed identity token or "(IT)." Trust Stamp believes this technology provides an unparalleled level of data protection, while improving the efficiency and expanding the utility of legacy identity systems. Trust Stamp CEO, Gareth N. Genner comments, "This will be our fourteenth issued patent, and we have an additional 19 patent applications pending. We're proud to be at the forefront of using AI for these types of applications, this patent contributes to an overall depth of technology innovation that allows us to deliver identity and trust-focused solutions that place privacy first."

08:43 EST Standard BioTools announces inducement grants under Nasdaq listing rule - Standard BioTools announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of February 20, 2023, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan, as a material inducement to four individuals entering into employment with Standard BioTools. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). In connection with the individuals entering into employment with Standard BioTools as new employees, none of whom were previously employees or directors of Standard BioTools, the individuals received awards totaling an aggregate of 85,000 restricted stock units. For each employee receiving an RSU Award, 1/4th of the total number of shares of common stock underlying each RSU Award will vest on February 20, 2024, and 1/16th of the shares will vest every three months thereafter until fully vested; provided, however, that if a vesting date would otherwise fall on a day when the national stock exchange upon which the shares are listed is not open for trading, vesting will occur on the first trading day thereafter. Vesting of the RSU Awards is subject to the employee continuing to be a service provider through each such vesting date, in addition to other terms and conditions of the Plan.

08:43 EST PLBY Group announces $70M debt paydown - PLBY Group announced that it amended its senior secured credit agreement and has made prepayments under the Credit Agreement in the aggregate amount of $70 million, resulting in the Company securing a waiver of applicable net leverage ratio covenants through the second quarter of 2024. The Company used $45 million of the proceeds from its previously announced $65 million capital raise for repayment of senior debt under the Credit Agreement. With such repayment, along with the $25 million repaid in December 2022, the Company has repaid $70 million of the senior debt in the past three months. The Company's current outstanding senior debt under the Credit Agreement is approximately $157 million.

08:42 EST InterDigital announces preliminary results of tender offer - InterDigital announced the preliminary results of its modified "Dutch auction" tender offer to purchase up to $200 million of its common stock for cash at a price per share not less than $65.25 and not greater than $75.00, which expired at 11:59 p.m., New York City time, on February 17, 2023. Based on the preliminary count by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, a total of 2,739,726 shares of InterDigital's common stock, $0.01 par value per share, were properly tendered and not properly withdrawn at or below the purchase price of $73.00 per share, including 633,565 shares that were tendered by notice of guaranteed delivery. In accordance with the terms and conditions of the tender offer, and based on the preliminary count by the depositary, the Company expects to acquire 2,739,726 shares of its common stock at a price of $73.00 per share, for an aggregate cost of approximately $200 million, excluding fees, expenses and excise tax relating to the tender offer. The 2,739,726 shares that the Company expects to accept for purchase represent approximately 9.2% of the Company's shares outstanding as of February 17, 2023. As such, the Company has been informed by the depositary that the preliminary proration factor for the tender offer is approximately 95.07%.

08:40 EST Predictive Oncology launches Accelerating Compound Exploration program - Predictive Oncology announced the launch of ACE, a program to advance the oncology drug development initiatives with academic and research institutions. Predictive Oncology created ACE to grant early-stage academic drug development groups and technology transfer offices access to the company's PEDAL platform. PEDAL pairs active machine learning with an extensive biobank of 150K privately held tumor samples and in vitro assay results to help evaluate drug compounds and enable more informed selection of drug-tumor type combinations. PEDAL helps efficiently address tumor heterogeneity earlier in development and offers researchers the ability to strengthen the data package for preclinical drug compounds in areas of licensing, increased likelihood of transferring the technology, de-risking the transaction, the chance to lead at the cutting edge of discovery and the opportunity to help biopharma advance their drug development efforts. Compounds selected for the ACE program will be included in PEDAL campaigns with shared non-exclusive rights to the resultant tumor response data. Participation will be provided at no up-front cost to the investigator or institution. Applications are being accepted at https://predictive-oncology.com/ace/ through March 31 for the first phase of the ACE program.

08:39 EST Bright Green refutes allegations made by Jerry Capussi, John Fikany - The company said, "The Company remains focused on continued execution of its business plan and is awaiting full approval from the U.S. Drug Enforcement Administration. Bright Green refutes the claims made by Mr. Capussi and Mr. Fikany, specifically: Mr. Fikany has never been, nor offered the role, of Chief Executive Officer of Bright Green Corporation. Bright Green has been and remains fully compliant in both its listing on the Nasdaq and its Securities and Exchange Commission reporting before and following the listing. There have been no allegations of securities fraud. Litigation between John Stockwell and/or the Stockwell family related to prior relationships with Mr. Capussi and Mr. Fikany are not applicable to Bright Green and are subject to a separate litigation that includes damages and defamation for false accusations made against the Stockwell family. The Company is taking action to address the aforementioned false claims and remains focused on the execution of its strategy, to include processing the first applications following the announcement of the United States Citizenship and Immigration Services' EB-5 program last week, and remains focused on concluding the DEA registration process, an important milestone for the Company."

08:37 EST Imax reports $24M four-day global box office for Disney's "Ant-Man" film - Imax (IMAX) announced that Disney's (DIS) "Ant-Man and the Wasp: Quantumania" debuted with a $24M four-day worldwide opening in IMAX - more than the previous two "Ant-Man" films combined. The film scored a $12.2M four-day Domestic IMAX opening, good for an outsized 10% of the overall Domestic box office. The IMAX China network delivered 21% of the four-day opening of "Ant-Man and the Wasp: Quantumania" on less than 1% of screens. The film debuted to a $4M four-day Imax gross in China. Imax delivered $11.8M in International box office for "Ant-Man" across 77 countries and territories. "Ant-Man and the Wasp: Quantumania" was shot with Imax digital cameras and features select scenes with Imax-exclusive expanded aspect ratio.

08:36 EST Mobiquity Technologies enhances AI capabilities with integration of ChatGPT - Mobiquity Technologies announces that it has integrated OpenAI's ChatGPT technology into its MobiExchange platform. The move will enhance the company's Artificial Intelligence offerings, providing advertisers with highly targeted, contextually relevant audiences and related ad copy. Dean Julia, CEO of Mobiquity Technologies, stated: "We are thrilled to integrate OpenAI's ChatGPT technology into our MobiExchange platform, which is already one of the quickest, easiest, and most cost-effective solutions for any size advertisers to launch a digital media campaign. We believe OpenAI has developed one of the most innovative and disruptive technologies to hit the market in a while and we look forward to adding more and more functionality to provide our clients with the tools needed to achieve the outstanding results they have come to expect from us."

08:35 EST Aileron Therapeutics to reduce workforce from nine to three full-time employees - Aileron has determined to reduce its remaining workforce from 9 to 3 full-time employees in the coming weeks. The company plans to retain the remaining employees to assist in executing the strategic alternatives review process. "We are very disappointed by these initial findings from our breast cancer trial, given the significant unmet need of cancer patients who must endure a wide range of chemotherapy-induced side effects and given the activity we had observed in our clinical trial in small cell lung cancer patients receiving topotecan chemotherapy. I would like to extend a heartfelt thanks to our patients, investigators and clinical trial staff and scientific advisors, as well as all others who have supported this trial and our efforts to advance ALRN-6924 as a chemoprotective agent. I would also like to thank our talented and truly dedicated Aileron team who have worked so diligently to advance ALRN-6924," said CEO Manuel Aivado. "We certainly hoped for a much different outcome for patients, but it is imperative that we now shift our focus toward conserving our resources as we explore strategic alternatives to maximize shareholder value."

08:34 EST Home Depot to invest $1B in annualized compensation for hourly associates - The Home Depot's associates are a key differentiator and competitive advantage for the company. In alignment with its core values, the company will invest in wage, benefits, training, and career development for its associates. Beginning in the first quarter of fiscal 2023, The Home Depot will invest an additional approximately $1B in annualized compensation for frontline, hourly associates.

08:32 EST ClearSign announces second boiler burner sale - ClearSign Technologies announces another sale of their fire tube boiler burner technology into the California market to a national service provider of recycling services to the food production and restaurant industries. The boiler burner will be installed with a new boiler and was sold as a package with our partner California Boiler into the San Joaquin Valley Air Pollution Control District of California. The burner and boiler are scheduled to be installed in the third quarter of 2023.

08:27 EST Siyata Mobile receives $750,000 order for PoC solution - Siyata Mobile announced it has received an order for $750,000 for its next-generation MCPTT solution to equip an independent emergency management service provider. The order includes the Company's SD7 devices and related accessories.

08:26 EST Walmart sees sales growth strongest in 1H, moderating in 2H

08:25 EST Red Cat CEO to visit NATO countries for talks on drone support for Ukraine - Red Cat announces that a delegation including CEO Jeff Thompson will visit NATO countries this week to discuss military drone support for Ukrainian forces. Thompson will meet with NATO leaders to demonstrate the Teal 2, a new military-grade drone from Red Cat subsidiary Teal Drones. Currently available to first-adopter customers and expected to officially launch in Q2 2023, Teal 2 is designed to "Dominate the Night" and will be the world-leading drone solution for nighttime operations. "In Ukraine and elsewhere, most military operations take place at night, and the Teal 2 gives warfighters exactly the solution they need," said Thompson. "Teal 2 is the first drone to integrate the world's best new night-time drone camera - next-generation thermal-imaging technology from Teledyne FLIR. We've also partnered with other industry leaders, such as Tomahawk Robotics, Reveal Technology and Immervision, to offer additional game-changing drone capabilities. These include multi-vehicle control, 3D mapping and object detection."

08:23 EST Walmart sees gross margin levels up in FY24, but not back to FY22 levels

08:22 EST Franklin Electric announces increase in its stock repurchase program - Franklin Electric announced that its Board of Directors approved a 1,000,000 share increase to its stock repurchase program. This is in addition to the approximately 216,000 shares that remain authorized for repurchase under the existing stock repurchase program. "We are pleased to increase our share repurchase authorization, which is enabled by our consistent operational performance and our healthy financial position. This announcement also reflects the Board of Directors' confidence in our business strategy and our long-term growth opportunities. We remain committed to allocating capital to profitable growth initiatives and returning capital to our shareholders through dividends and share repurchases," commented Gregg Sengstack, Franklin Electric's Chairperson and CEO.

08:19 EST Walmart expects operating income growth to outpace sales growth in FY24 -

08:17 EST Beam receives order from City of Austin, Texas for sustainable EV charging - Beam Global announced that it received an order for EV ARC solar-powered EV charging and ARC Mobility trailer solutions from the City of Austin in Texas. The systems were purchased using the federal General Services Administration Multiple Award Schedule Contract Number 47QSWA21D0006. The City of Austin also awarded Beam Global a contract, including the Company's GSA listed products, which streamlines the purchase process for City departments, without going through extensive individual contracting requirements. "The recent increase in orders from different Texas government entities mirrors the disaster preparedness plans gaining funding and momentum across the United States and internationally," said Beam Global CEO Desmond Wheatley. "Electric vehicle operators need access to charging during increasingly frequent grid outages. Our EV ARC solar-powered systems provide vital EV charging and emergency power during utility grid power failures. We are seeing increasing sales from entities that need EV charging faster than traditional construction projects allow and disaster preparedness at all times. EV ARC systems solve for both requirements."

08:15 EST IntelGenx receives USPTO notice of allowance for loxapine patent - IntelGenx announced that the United States Patent and Trademark Office has granted a Notice of Allowance for U.S. Patent Application 16/053,383, entitled "Loxapine Film Oral Dosage Form." This film formulation patent covers Loxapine oral film formulations designed for use in patients with anxiety and agitation associated with schizophrenia and bipolar 1 disorder, and is intended to protect IntelGenx' Loxapine VersaFilm product. The new, soon to be patented, Loxapine oral film technology is designed to provide quick onset and a simple administration process for schizophrenia and bipolar 1 disorder patients. Currently, the marketed loxapine product for agitation treatment in schizophrenia and bipolar mania is an inhaler that can only be administered at certified healthcare settings under supervision of a physician. IntelGenx's Loxapine VersaFilm is intended as a rescue medication which can be administered by caregivers and, therefore, has the potential to increase availability of the drug to patients.

08:13 EST Walmart sees 'stubborn' inflation in grocery, consumables this year - Comments taken from Q4 earnings conference call.

08:13 EST electroCore announces exclusive distribution agreement with Byond Healthcare - electroCore announced an agreement with Byond Healthcare Pty to serve as the exclusive distributor of gammaCore Sapphire, non-invasive vagus nerve stimulator, nVNS, in South Africa and Namibia. "Access to exceptional medical technologies is key to improving healthcare outcomes," said David Loubser, Managing Director of Byond Healthcare. "It is a privilege for Byond to provide clinicians in South Africa and Namibia with a cutting-edge, clinically proven tool that we believe can help combat the opioid crisis by treating a variety of pain conditions with a non-pharmaceutical therapeutic option. Cleared by reputable authorities such as the U.S. FDA, TGA, Health Canada, and EU, gammaCore is a practical solution that aligns with Byond's focus on making innovative pain management technologies accessible to both patients and healthcare providers. As a first-line treatment option for primary headache-related pain, gammaCore is a perfect fit for Byond's mission." The initial term of the agreement is three years and contains customary terms and conditions, and regulatory clearances are required before sales and revenue can occur.

08:11 EST Harsco says Fullcircle program exceeded 2022 growth target - Harsco Corporation announced that its Clean Earth division's Fullcircle program exceeded its 2022 growth target and helped customers achieve their sustainability goals. Last year, the Fullcircle program transformed over 16 million pounds of soap-like by-product into an industrial cleaner, converted over 23 million pounds of waste material to more sustainable engineered fuel solutions, and diverted over 1 million pounds of bulk-making waste from traditional disposal to compost. Fullcircle is Clean Earth's Advanced Waste Lifecycle Program, a concierge service that carefully and strategically analyzes waste before it even happens. From initial product concept to lifecycle completion and everything in between, the Fullcircle program provides solutions that aim to eliminate all the waste, recycle as much as possible, and build a scalable program for customers focused on zero waste.

08:09 EST Everi Holdings signs long-term mobile solutions agreement with 1839 Labs - Everi Holdings' Venuetize, a mobile technology and e-commerce platform for the sports, hospitality, and entertainment industries, has entered into a strategic agreement with 1839 Labs pursuant to which the companies will integrate their respective solutions to elevate the experience of fans, spectators, and guests within sporting and other mixed-use venues around the globe. The long-term engagement will commence with the initial mobile deployment specific to the Balaton Gate Motor Speedway, opening this Spring, and expand the mobile experience across the property as a resort and additional hospitality projects are completed.

08:09 EST Adeia renews IP license agreement with Altice USA - Adeia (ADEA) announced that Altice USA (ATUS), a leading provider of broadband, video, mobile, proprietary content and advertising services, signed an early renewal agreement extending their license to Adeia's media intellectual property portfolio, which supports Altice's Optimum services, including their cable TV and over-the-top streaming services. "We are pleased to announce this early renewal, which extends our long term relationship with Altice. The US pay-TV market is among the most competitive environments in the world. Leaders in this segment, including Altice, are leveraging innovations that improve digital entertainment experiences to help consumers quickly, easily and intuitively find the content and services they want to enjoy," said Paul E. Davis, chief executive officer of Adeia.

08:08 EST Arrival announces $50M equity capital commitment - Arrival announced it will raise up to $50M of new equity capital through the sale of new common stock to Antara Capital Master Fund LP and will exchange $121.9 million principal amount of 3.50% convertible notes due 2026 held by Antara for additional equity, thereby significantly reducing the Company's debt and improving the Company's liquidity position. Under the terms of the transaction agreements, Arrival will issue 125 million shares of new equity in exchange for $25 million of cash. Antara has also committed to provide a further $25 million of additional capital to be invested from time to time after 15 May 2023 and no later than 30 June 2023 by subscribing for additional equity at a price no greater than $0.20/share. The closing price for Arrival shares on February 17, 2023 was $0.33. The additional $50 million of capital will support the ongoing development of Arrival's products. In addition, Antara has agreed to convert $121.9 million of Notes into 219,420,000 ordinary shares. After the exchange, the face amount of Arrival's remaining principal of convertible notes outstanding will be $198.1 million, a reduction of 38 percent, and future annual cash interest expense will be lowered by approximately $4.2 million. As part of the transaction agreements, Antara has committed to hold 100 million of newly issued shares for a period of 12 months and has provided the Company the right to repurchase the Lock-Up Shares within the same 12 month period at a price of $0.40 per share. The capital raise and debt exchange are subject to customary closing conditions.

08:07 EST Gogo patent infringement complaint from SmartSky adds two recent patents - SmartSky Networks has asked the U.S. District Court in Delaware to add two recently issued patents to its 2022 infringement lawsuit against Gogo Business Aviation and Gogo. The newly amended complaint alleges that Gogo has been illegally selling and offering to sell its "5G," air-to-ground internet connectivity product in violation of SmartSky's patented inventions. The two new patents are related to patents included in the original complaint and directly negate several of Gogo's non-infringement arguments. The '108 Patent is part of a family of patents from inventor Donald Alcorn previously asserted in the lawsuit. The claimed invention enables the "handoff" of a data communications link between an aircraft and a network of ground base stations. The second new patent, the '639 Patent, is part of a family of patents from inventor Douglas Hyslop that together cover how base stations are arrayed in a wedge-shaped architecture in broadband, ATG wireless communications systems. The amended complaint increases the number of patents at issue in the lawsuit from 4 to 6. If the Court finds infringement of any one claim of any one patent, SmartSky would effectively win the case and Gogo could be permanently blocked from selling and operating its 5G system, which may include blocking the sale or use of the required Avance L5 system component, as well. A separate panel of three federal appeals court judges are considering SmartSky's motion for preliminary injunction that could immediately bar Gogo from selling its "5G" system. Their decision could come late Spring of this year.

08:06 EST Caligan Partners urges significant change at Anika, including strategic review - Caligan Partners, one of the largest shareholders of Anika Therapeutics, issued an open letter to the board of directors of Anika in connection with Anika's poor share performance, caused by the heavy losses it is incurring in its joint preservation segment, and its failure to maximize the value of Anika's visco supplement portfolio. Caligan offered actions for significant change, including a strategic review. Reference Link

08:05 EST U.S. Energy announces 24% increase to year-end 2022 PDP reserves - U.S. Energy announced its 2022 proved reserves and provided an update on its fourth quarter 2022 production, year-end balance sheet, and liquidity. Increased year-end 2022 proved developed producing reserves by 24% to 7.8 million barrels of oil equivalent, of which 65% is crude oil, from 6.3 MMBoe at year-end 2021, of which 80% was crude oil; Grew fourth quarter 2022 average daily production to 1,918 barrels of oil equivalent per day, representing a 453% increase over fourth quarter 2021 and a 9% increase over third quarter 2022. Exited 2022 with debt of $12.0 million and cash of $4.1 million for total liquidity of $12.1 million. "U.S. Energy was successful in 2022 executing on our stated acquisition strategy of opportunistically adding significant reserves while maintaining an excellent balance sheet," said Ryan Smith, U.S. Energy's Chief Executive Officer. "We are pleased to report strong year-end 2022 proved reserves with our year-end SEC reserve report, prepared by an independent third party, showing an increase of 24% in proved producing reserves."

08:03 EST Alnylam announces FDA acceptance of patisiran sNDA - Alnylam announced that the FDA has accepted for filing the company's supplemental new drug application, or sNDA, for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated, or ATTR, amyloidosis. The FDA has set an action date of October 8 under the Prescription Drug User Fee Act, or PDUFA. In their file acceptance letter, the FDA stated that they have not identified any review issues. The agency also noted that they are planning to hold an advisory committee meeting to discuss the application. Patisiran is the established name for Onpattro, which is currently approved by the FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.

08:02 EST MingZhu Logistics to acquire Alliance Liquor - MingZhu Logistics announced it has entered into a non-binding memorandum of understanding to acquire Guizhou Alliance Liquor Management Co., Ltd., a China-based distributor of Baijiu. The companies plan to further invest in and develop a commercial liquor distribution business across China. Alliance Liquor is a liquor distributor that focuses on distributing Baijiu brewed in Maotai town, Guizhou. Baijiu is considered to be China's national drink and is the dominant spirits sold in the domestic China market, with the "white liquor" a normal staple at occasions from family gatherings to business banquets while the Maotai town is the most well-known origin of Baijiu. Under the agreement, once the acquisition is completed, Alliance Liquor will develop its own Baijiu brand and high-end liquor customization OBM services.

07:58 EST Telos expands federal and commercial business team - Telos Corporation announced the addition of two executives to expand Telos' federal and commercial business. Joining the team is industry veteran and cybersecurity expert Josh Salmanson, the Company's senior vice president of Technology Solutions, and Lee Canterbury, the Company's vice president of Corporate Growth. As a senior business leader, Salmanson has led multiple high-performance teams on large programs of record for leading systems integrators and aerospace and defense firms. Canterbury served in executive positions at SAIC, General Dynamics IT, and other federal technology companies.

07:56 EST Fairfax Financial announces personnel changes - Fairfax Financial Holdings announces that, in connection with recent management changes at Odyssey Group, Brian Young, CEO of Odyssey Group, will begin to share oversight responsibilities with Andy Barnard, President of Fairfax Insurance Group, over all of Fairfax's insurance and reinsurance operations. Brian Young will continue as CEO of Odyssey Group and, effective April 1, 2023, Carl Overy, presently CEO of Odyssey's London Market Division, will become CEO of Odyssey's Global Reinsurance Business. Bob Pollock, presently head of Odyssey's U.S. Financial Lines, Cyber and Worker's Compensation business, will become CEO of Odyssey's London Market Division and report to Carl. Carl will report to Brian in his continuing capacity as CEO of Odyssey Group.

07:41 EST Drakewell joins Rekor Partner Network - Rekor Systems announced that Drakewell has joined the Rekor Partner Network. The RPN has been designed to enable and simplify roadway data analysis for transportation agencies, corporations, and private firms through its state-of-the-art software suite. The RPN is a global ecosystem of technology, data, and solution providers working together to generate the most comprehensive view of roadway data and intelligence available to solve transportation and mobility challenges and streamline innovation.

07:39 EST NextSource completes processing plant construction for Molo Graphite Mine - NextSource Materials announced that construction of the processing plant and mining camp for the Company's Molo Graphite Mine in Madagascar is now complete, and that the entire mining fleet is at site. Electrical interconnections between plant modules are in progress, which will be followed by commissioning and the start of mining activities. Plant commissioning will be followed by a ramp up period of up to three months prior to achieving commercial production. Phase 1 of the Molo Graphite Mine is designed to process 240,000 tonnes per annum of ore resulting in a name plate production capacity of 17,000 tpa of flake graphite.

07:38 EST Meihua signs construction agreements for technology park and medical center - Meihua, via its subsidiary company Hainan Guoxie, has entered into cooperation agreement with Qionghai City of Hainan Province to build a technology park project. Hainan Guoxie also entered into a cooperation agreement with Hainan Free Trade Port Boao Hope City to build MHUA a medical research and development center in the Hope City. Pursuant to the Qionghai Agreement, Hainan Guoxie plans to invest in the construction of a medical industrial park in Hainan Province focused on the development of minimally invasive interventional medical devices, new materials and surgical robotics technologies. Pursuant to the Hope City Agreement, the planned MHUA medical R&D center will carry out the research and development of stem cell to human targeted therapies and rehabilitation training projects. Hope City is the only special medical park in China.

07:38 EST Almaden Minerals signs cooperation agreement with Ejido Santa Maria Zotoltepec - Almaden Minerals reports that it has recently signed a cooperation agreement with the Ejido Santa Maria Zotoltepec, the Ejido located closest to the Ixtaca project, in Puebla State, Mexico. This agreement is similar to the one signed last year with the "United Ejidatarios for the Sustainable Development of Santa Maria Zotoltepec, A.C.," but it is signed with the entire Ejido after a majority vote in favour under strict agrarian rules and signed through an Act of Assembly. The agreement is initially focused on contributions to support an agro-technological package aimed at sustainable plant nutrition and soil enrichment. Longer term, the agreement commits the parties to work collaboratively under the Project's Social Management Plan in pursuit of multiple UN Sustainable Development Goals. Duane Poliquin, Chair of Almaden, stated "We have felt welcomed in Santa Maria since first arriving in the area many years ago, and are pleased to be able to formalise our relationship with the local Ejido. The practices captured by this agreement have been in place for many years; continuous respectful dialogue with the overarching objective of building a mine the Company and local communities can be proud of. This agreement cements this approach through local leadership and sets us up to continue delivering on such fundamental priorities as water rights, education, health, opportunity, workers' rights, environment, culture, and more."

07:35 EST Vinco anticipates imminent filing of Quarterly Report for quarter ended June 30 - Vinco Ventures announces that it anticipates its imminent filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 with the SEC reflecting the culmination of the diligence of its finance team and its auditors. The Company plans to file its Quarterly Report on Form 10-Q for the quarter ended September 30th, 2022 on or before March 8, 2023.

07:34 EST Cambium Networks announces contract with FBI - Cambium Networks announced its latest contract with the Federal Bureau of Investigation. The FBI will be using Cambium Networks' fixed wireless microwave broadband radios in support of the Bureau's national security video surveillance program. To date and with this current order, Cambium Networks has deployed over 160 systems for the FBI.

07:30 EST Draganfly to showcase drone, AI technology at World Police Summit - Draganfly announced its participation in the World Police Summit from March 7 to 9, 2023 at the Dubai World Trade Centre. During this two-day event, Draganfly's team will be available at booth 8A29 to educate and provide a hands-on look at its technology. "We are thrilled to be involved in this year's World Police Summit in Dubai and demonstrate how our drone and AI technology is helping law enforcement enhance situational awareness," said Cameron Chell, President, and CEO of Draganfly. "Draganfly has a long and proud history of supporting law enforcement agencies in keeping the public safe. Our team is always looking for solutions to protect lives, mitigate risk, and reduce liability for public safety agencies."

07:28 EST Evoke, EVERSANA to present study results comparing GIMOTI, oral metoclopramide - Evoke Pharma and EVERSANA announced that its abstract entitled "Reducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gastroparesis Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide" has been selected for the plenary lecture presentation at the upcoming Digestive Disease Week 2023. The meeting will take place May 6-9, 2023 at McCormick Place in Chicago, IL. The abstract will be delivered in an oral plenary presentation by David C. Kunkel, MD, Gastroenterologist and Associate Professor of Medicine at UC San Diego Health. Sessions at DDW are the forum for highlighting some of the year's best research abstracts as determined by the conference organizers. The presentation will highlight data from a retrospective cohort analysis of 514 diabetic gastroparesis patients comparing those receiving either GIMOTI or oral metoclopramide to determine the relative usage of healthcare resources across several settings, such as physician's offices, emergency rooms, and inpatient and outpatient hospital visits. GIMOTI is the first and only FDA-approved nasal formulation of metoclopramide that is commercially available and specifically designed to deliver a non-oral dose of metoclopramide for the relief of symptoms in adults with acute and recurrent DGP. Prior to GIMOTI's approval by the U.S. Food and Drug Administration, oral metoclopramide was the only FDA-approved outpatient treatment for patients suffering from DGP. A nasal route of administration offers systemic absorption in patients with gastroparesis where gastric emptying can be erratic and absorption of oral medications can be unpredictable.

07:25 EST Janus International appoints David Vanevenhoven Chief Accounting Officer - Janus International Group (JBI) announced the appointment of David Vanevenhoven as Chief Accounting Officer, on February 20 . He will report directly to Janus's CFO, Anselm Wong. Mr. Vanevenhoven brings over 15 years of experience in financial accounting and auditing to oversee Janus's accounting function, financial reporting, and internal controls. Vanevenhoven has a proven history of leading financial and regulatory reporting, auditing, and mergers and acquisitions teams, including financial due diligence and integration of several transactions. Prior to joining the Company, Mr. Vanevenhoven served as Global Controller at Mirion Technologies ( MIR), where he led the accounting for and integration of eight different acquisitions / divestitures and was highly involved in their successful SPAC merger to become a public company.

07:24 EST Bowman Consulting awarded $5M multi-year on-call contract from MBTA - Bowman Consulting announced it has been awarded a $5M multi-year on-call contract to provide bus system infrastructure improvements for the Massachusetts Bay Transportation Authority, or MBTA. Assignments under the contract will focus on enhancing the efficiency and reliability of bus operations and improving the passenger experience along the system's 171 bus routes. This award is a continuation of on-call services the firm has been providing MBTA for the past four years. The direct assignment was awarded to Bowman's wholly owned McMahon subsidiary as prime consultant for planning, design and construction phase services.

07:22 EST Osino provides update on H1 2023 exploration budget at Twin Hills Gold project - Osino Resources provides an update on its H1 2023 exploration budget for its wholly owned Twin Hills Gold Project. David Underwood, Osino's VP Exploration commented: "With this round of drilling Osino aims to further grow the Twin Hills mineral resource by chasing previously identified mineralised shoots and stepping out along strike and at depth. We also aim to increase the reserve by converting inferred ounces to indicated, which will allow them to be included in the DFS and produce a more even gold production profile. In addition, we are now refocusing on near-pit exploration by testing some of our excellent targets and surface anomalies. We are particularly excited about the district targets at OJW and Rheinsheim which have large surface geochemical expressions, good rock chip and channel results on surface, and have never been drill-tested before. Any ounces discovered at these targets or at Twin Hills East will be within easy trucking distance of the plant and will add immediate value at low cost and low risk."

07:22 EST OKYO Pharma to present at second annual GPCRs-targeted drug discovery summit - OKYO Pharma Limited announced that its CEO, Gary Jacob, Ph.D., will be giving an oral presentation entitled: "A Lipidated Protease-Resistant Chemerin Peptide Offers a Novel Therapeutic for Dry Eyes" on February 22, 2023 at the 2nd Annual GPCRs-Targeted Drug Discovery Summit at the Hyatt Regency in Boston, MA. Dr. Jacob's talk, which is scheduled for the afternoon of February 22, will cover the planned clinical development of OKYO's drug candidate OK-101 to treat dry eye disease.

07:19 EST Algernon initiates traumatic brain injury research program with DMT - Algernon Pharmaceuticals announced that its subsidiary Algernon NeuroScience has added a new clinical research program for the treatment of Traumatic Brain Injury with AP-188. AGN Neuro plans to be the first company globally to investigate DMT for TBI in humans and is planning to begin a Phase 2 clinical trial in Q4, 2023. AGN Neuro has an active stroke research program underway and is currently conducting a Phase 1 DMT study in the Netherlands at the Centre for Human Drug Research. It recently announced that it had completed dosing subjects in the first cohort of the study and that the safety review committee has approved moving the study forward with the next cohort at an escalated dose after observing no safety or tolerability issues. AGN Neuro's clinical plan is to use the data from the Phase 1 Study of DMT currently underway, to accelerate directly into a Phase 2 TBI study in the fall of 2023. AGN Neuro, in consultation with its TBI advisors, may plan and conduct certain preclinical research to help better guide the planned Phase 2 clinical study. AGN Neuro's decision to investigate DMT for TBI is based on several factors, specifically:There are many commonalities between stroke and TBI where DMT has demonstrated benefit in several preclinical studies, including: neuroinflammation, mitochondrial dysfunction, reactive oxygen species, excitotoxicity, and spreading depolarizations. DMT is an agonist of sigma-1, a part of the body's natural defense against physiological stresses, which is elevated following TBI. DMT increases brain derived neurotropic factor, a protein which plays a key role in neuroplasticity. Natural levels of BDNF in the brain are decreased following TBI; however, expression of TrkB mRNA, the receptor to which BDNF binds, is increased as the brain seeks to compensate for the injury. Studies have shown that exercise-induced increases in BDNF generally improve recovery following TBI, and that blocking the effects of BDNF attenuate the improvement. Furthermore, increased levels of BDNF following TBI are correlated with improved cognitive function. On-going symptoms of TBI are often psychological and cognitive; a number of psychedelic drugs, including DMT, have already shown therapeutic potential in clinical trials in some of these conditions. In TBI, classified as mild according to the Glasgow coma scale, up to 50% of TBI patients have symptoms that have not resolved after 6 months. Millions of mild TBIs occur each year, and that number is expanding with increased access to motor vehicles in the developing world and the associated increase in accidents. There are currently no drugs approved for treatment of TBI of any severity.

07:16 EST First Wave BioPharma to present Phase 2 adrulipase combination trial data - First Wave BioPharma announced that an abstract entitled, "Results from an Open-Label, Phase 2 Study with Escalating Doses of Adrulipase Alfa on top of a Stable Dose of Porcine Pancreatic Enzymes in CF Patients Not Fully Compensated with PPE as Sole Therapy," has been accepted for a presentation at the 2023 Digestive Disease Week Conference. The conference is taking place May 6-9, 2023, in Chicago. The presentation by Michael Konstan, M.D., Vice Dean for Translational Research at Case Western Reserve University School of Medicine and a clinical expert in exocrine pancreatic insufficiency in patients with cystic fibrosis, will share data from the Phase 2 adrulipase Combination Therapy Trial which evaluated the safety and efficacy of adrulipase in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy, for the treatment of severe EPI in patients with CF. Presentation Title: Results from an Open-Label, Phase 2 STUDY with Escalating Doses of Adrulipase Alfa on top of a Stable Dose of Porcine Pancreatic Enzymes in CF Patients Not Fully Compensated with PPE as Sole Therapy Presenter: Michael Konstan, M.D., Vice Dean for Translational Research and the Gertrude Lee Chandler Tucker Professor of Pediatrics at Case Western Reserve University School of Medicine Session Title: Exocrine Pancreatic Disease Date and Time: May 7, 2023, at 10:45 a.m. CDT First Wave BioPharma is currently advancing the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase as a monotherapy for the treatment of exocrine pancreatic insufficiency in patients CF. Patient dosing is expected to commence in February with topline results from the study to be available by mid-2023.

07:16 EST CVRx reports preliminary results of BeAT-HF post-market clinical trial - CVRx announced the preliminary topline results of the BeAT-HF, Baroreflex Activation Therapy for Heart Failure, post-market randomized clinical trial. The BeAT-HF post-market phase of the multi-center, prospective, randomized, controlled trial assessed 323 patients suffering from heart failure with reduced ejection fraction. The primary endpoint was a composite of cardiovascular mortality and heart failure morbidity. While the trial did not reach statistical significance on the primary endpoint, it did contain additional clinically meaningful prespecified analyses that favored Barostim, including: all-cause survival, free from LVAD and heart transplant; a hierarchical composite analysis of cardiovascular mortality, heart failure events and quality of life; and a clinical stability analysis. In addition, the safety profile of Barostim and the symptomatic improvement at 6 months, that were the basis for the FDA pre-market approval, were shown to be durable through 24 months. "We are grateful to all the patients who enrolled in BeAT-HF, to the investigators in the 108 clinical sites and to the Executive Steering Committee for their dedicated effort over the years," said Nadim Yared, President and CEO of CVRx. "This new evidence is welcome news for the many patients with heart failure, who remain symptomatic despite optimal medical therapy. We plan to submit the totality of evidence of BeAT-HF to FDA seeking an expansion of Barostim labeling."

07:13 EST Optinose submits sNDA to U.S. FDA for XCHANCE label expansion - Optinose announced the submission of its supplemental new drug application, sNDA, to the U.S. Food and Drug Administration, FDA, to request approval of XHANCE as a treatment for chronic rhinosinusitis. The sNDA submission is based on data from the two Phase 3 clinical trials from the ReOpen Program in patients suffering from chronic sinusitis and was submitted to the FDA on February 16, 2023. "We are pleased to announce completion of this sNDA submission for XHANCE. The submission marks an important milestone in our progress towards changing the standard of care for approximately 10 million people in the United States with chronic rhinosinusitis who seek physician treatment annually, particularly the majority who do not have nasal polyps and for whom there are currently no FDA-approved drug treatments," stated Ramy Mahmoud, MD, MPH, CEO of Optinose. "I would like to thank the patients whose altruism made this advance possible, and both the healthcare providers worldwide and my colleagues at Optinose whose hard work and dedication enabled the entire program and submission."

07:11 EST Tela Bio announces U.S. commercial launch of two OviTex LPR configurations - TELA Bio announced the launch of two additional, larger configurations of its OviTex LPR device. The new configurations are 15 x 20 cm and 15 x 25 cm ellipses designed for ventral and incisional hernias. OviTex LPR is designed specifically for use in minimally invasive hernia repair procedures. Its low profile facilitates placement through robotic and laparoscopic ports, and it incorporates a smooth side for placement within the abdominal cavity adjacent to the viscera. "Since inception, a key design principle for OviTex has been to provide a platform that can be used for all hernia indications and surgical techniques," said Antony Koblish, President and CEO of TELA Bio. "OviTex LPR has gained exceptional adoption among surgeons using minimally invasive techniques and the new larger configurations will help drive broader utilization in robotic and laparoscopic procedures."

07:09 EST LGI Homes sees 2023 home closings 6,000-7,000 - Subject to the caveats in the Forward-Looking Statements section of this press release, the Company is providing the following guidance for the full year 2023. The Company expects: Home closings between 6,000 and 7,000; Active selling communities at the end of 2023 between 115 and 125; Average sales price per home closed between $335,000 and $350,000; Gross margin as a percentage of home sales revenues between 21.0% and 23.0%; Adjusted gross margin as a percentage of home sales revenues between 22.5% and 24.5% with capitalized interest accounting for substantially all the difference between gross margin and adjusted gross margin; SG&A as a percentage of home sales revenues between 11.5% and 12.5%; Effective tax rate between 23.5% and 24.5%.

07:07 EST Chemomab Therapeutics' CM-101 INDA in systemic sclerosis approved by FDA - Chemomab Therapeutics announced FDA clearance of the company's Investigational New Drug - IND - Application to evaluate CM-101 in a Phase 2 trial in adults with systemic sclerosis, or SSc. CM-101 is a first-in-class monoclonal antibody designed to interfere with key biological pathways associated with SSc and other serious fibro-inflammatory diseases. In preclinical studies, CM-101 reduced inflammatory and fibrotic injury to the lung, skin and vasculature-organ systems often affected in SSc patients. In early clinical trials, CM-101 was well-tolerated, reducing fibrogenesis-related biomarkers and demonstrating anti-inflammatory effects. CM-101 has been granted Orphan Drug designation by the FDA for SSc and for primary sclerosing cholangitis, a rare liver disease. The CM-101 Phase 2 SPRING trial in PSC patients is currently ongoing.

06:55 EST Eneti subsidiary Seajacks UK signs contract in NW Europe - Eneti's Seajacks UK wholly-owned subsidiary has signed a contract in NW Europe for between 41 and 53 days of employment for one of its NG2500-class vessels that will generate between approximately $3.3M and $4.1M of revenue in 2023.

06:53 EST Teck Resources sees 2023 copper production 390K-445K tons - Sees 2023 zinc production 645K-685K tons, steelmaking coal 24-26 million tons.

06:50 EST Pfizer: FDA accepts for review BLA for RSV vaccine candidate - Pfizer announced that the U.S. FDA has accepted for review a Biologics License Application for its respiratory syncytial virus vaccine candidate PF-06928316 or RSVpreF for the prevention of medically attended lower respiratory tract illness (MA-LRTI) and severe MA-LRTI caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals. This decision follows the FDA's Breakthrough Therapy Designation for RSVpreF in March 2022. The FDA has accepted the BLA for priority review and has set a Prescription Drug User Fee Act action date of August 2023.

06:47 EST Akebia receives second interim response from FDA for vadadustat FDR - Akebia announced that the company received a second interim response from the FDA to its Formal Dispute Resolution Request, or FDR, regarding the Complete Response Letter for vadadustat received in March 2022. Akebia received notification from the Office of New Drugs, or OND, Center for Drug Evaluation and Research, that due to agency resource constraints and staffing needs the deciding authority for the appeal will now be Peter Stein. The appeal was originally assigned to a senior advisor within the OND.

06:41 EST Merck provides update on Phase 3 MOVe-AHEAD trial evaluating LAGEVRIO - Merck announced that LAGEVRIO did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual with COVID-19. The Phase 3 MOVe-AHEAD trial evaluated people who did not have COVID-19 at baseline (confirmed by a negative baseline SARS-CoV-2 test and no signs and symptoms) but lived with someone who was recently diagnosed with COVID-19. In the primary endpoint of participants who did not have evidence of SARS-CoV-2 infection at baseline (confirmed by a negative SARS-CoV-2 test), the LAGEVRIO treated group was observed to be 23.6% less likely than those who received placebo to develop COVID-19 through Day 14 (a positive post-baseline SARS-CoV-2 test with evidence of signs and symptoms); the primary endpoint was not met. The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies and post-authorization experience in the treatment of COVID-19. Merck intends to submit full results from this study for presentation at a scientific meeting or for publication.

06:22 EST Teck Resources announces agreement with Nippon Steel, POSCO - Teck has also reached agreement with its steelmaking coal joint venture partners and major customers, Nippon Steel Corporation and POSCO, to exchange their minority interests in the Elkview and Greenhills operations for interests in EVR. As a result, EVR will own 100% of its steelmaking coal operations. NSC's exchange of its Elkview interest and its $1.025 billion cash investment will give it a 10% interest in EVR common shares and the Transition Capital Structure. POSCO will receive a 2.5% interest in EVR common shares and the Transition Capital Structure. Pursuant to these transactions: NSC has agreed to exchange its current 2.5% interest in Elkview Operations and $1.025 billion in cash payable to Teck Metals for common shares of EVR and an interest in the Transition Capital Structure. This implies an EVR enterprise value of approximately $11.5 billion. Following these transactions, NSC will own 10% of the EVR common shares and a 10% interest in the Transition Capital Structure. EVR and NSC will enter into a long-term steelmaking coal offtake rights arrangement, continuing NSC's long-standing commercial arrangements for the purchase of steelmaking coal from the Elk Valley. EVR and NSC will enter into an investor rights agreement, pursuant to which NSC will be entitled to certain customary rights including a right to nominate one director to the board of directors of EVR, pre-emptive rights on future securities issuances, and registration rights. NSC will agree to certain customary transfer and standstill restrictions. POSCO has agreed to exchange its current 2.5% interest in Elkview Operations, and its 20% interest in the Greenhills joint venture, for a 2.5% interest in each of the EVR common shares and the Transition Capital Structure. The exchanges of the current interests of NSC and POSCO for interests in EVR are conditional on the completion of the Separation and other customary conditions. The additional investment by NSC is conditional on completion of the Separation, but the Separation is not conditional on completion of the additional investment by NSC.

06:20 EST Teck Resources to separate into two publicly-listed companies - Teck Resources announced the reorganization of its business to separate Teck into two independent, publicly-listed companies: Teck Metals Corp. and Elk Valley Resources Ltd. The Separation will create two world-class resource companies and provide investors with choice for allocating investment between two businesses with different commodity fundamentals and value propositions. Teck Metals will be growth-oriented, with premier, low-cost base metals production, a top-tier copper development portfolio and a disciplined capital returns policy. EVR will be a high-margin Canadian steelmaking coal producer, focused on long-term cash generation and providing cash returns to shareholders, with significant equity value accretion potential. Both companies will remain committed to strong environmental and social performance. The Separation is structured as a spin-off of Teck's steelmaking coal business by way of a distribution of EVR common shares to Teck shareholders. Teck Metals will retain a substantial interest in steelmaking coal cash flows through a transition period in the form of an 87.5% interest in a gross revenue royalty and preferred shares of EVR. Under the Transition Capital Structure, Teck Metals will receive quarterly payments consisting of Royalty payments and preferred share redemption amounts that will in aggregate equal 90% of EVR free cash flow. Teck shareholders of record as of the applicable distribution record date will receive common shares of EVR in proportion to their Teck shareholdings at an exchange ratio of 0.1 common share of EVR for each Teck share (or approximately 51.9 million total EVR common shares) and approximately $0.39 cash per share for an aggregate of $200 million in cash. Shareholders will be able to elect to maximize the amount of cash or common shares of EVR they receive, subject to proration, through a Dutch auction election process. Details of the election will be set out in the management proxy circular to be provided to Teck shareholders. As part of the Separation, Teck will change its name to Teck Metals Corp. and continue to be listed on the Toronto and New York stock exchanges. EVR has applied to have its common shares listed on the TSX. In consideration for the transfer of the steelmaking coal assets to EVR, EVR will grant the Royalty and issue preferred shares and common shares to Teck Metals. The Royalty is a 60% gross revenue royalty that will be paid quarterly from EVR's steelmaking coal revenue, subject to free cash flow and minimum cash balance limitations designed to support the financial resiliency of EVR, and should generally generate payments equal to 90% of EVR free cash flow. The Royalty will be payable until the later of (a) an aggregate amount of $7.0 billion in royalty payments having been made, or (b) December 31, 2028. The preferred shares will have an aggregate $4.4 billion redemption amount and a 6.5% cumulative dividend. The preferred shares will be redeemed out of 90% of EVR free cash flow after the Royalty is no longer payable. If not redeemed earlier, the preferred shares will mature 20 years from their date of issue. Assuming a US$185/tonne long-term benchmark steelmaking coal price and a CAD/US dollar exchange rate of 1.30, the Transition Capital Structure could be fully paid in approximately 11 years. Cash flow from the Transition Capital Structure is expected to provide Teck Metals with continued funding for prudent investment in its top-tier copper growth pipeline, while allowing for disciplined returns to its shareholders. Teck has received preliminary indications that S&P, Moody's and Fitch are likely to affirm an investment grade credit rating on the existing senior notes of Teck Metals should the Separation proceed. Teck will seek shareholder approval of the Separation at its annual and special meeting of shareholders expected to be held on or about April 26. Teck expects that the transaction will be completed in the second quarter of 2023.

06:16 EST Teck Resources to separate into two publicly-listed companies

06:09 EST Maxar Technologies to provide environmental monitoring for Government of Guyana - Maxar Technologies announced that the Guyana Ministry of Natural Resources has entered into a three-year contractual agreement with Maxar to provide the nation with environmental monitoring services for both offshore and terrestrial applications. Guyana's Environmental Protection Agency will utilize Maxar's Crow's Nest Maritime Monitoring and Security products to support offshore petroleum monitoring. The EPA will use the Crow's Nest Maritime Tipping and Cueing Service, which leverages Maxar's very-high resolution optical satellites, to monitor drilling vessels for regulatory compliance and safety. It will also use the Crow's Nest Multi-Sensor Oil Detection Service to identify potential spills. The agreement with Guyana marks Maxar's first Crow's Nest contract in Latin America and the Caribbean. Also included in the agreement, the Guyana Forestry Commission will combine several Maxar capabilities to track illegal deforestation, protect mangroves and safeguard the country's biodiversity.

06:08 EST Home Depot announces 10% increase in quarterly dividend to $2.09 per share - The company announced that its board of directors approved a 10% increase in its quarterly dividend to $2.09 per share, which equates to an annual dividend of $8.36 per share. The dividend is payable on March 23 to shareholders of record on the close of business on March 9. This is the 144th consecutive quarter the company has paid a cash dividend.

06:03 EST Teck Resources announces $250M share repurchase plan - The Board has authorized management to purchase up to $250M of Class B subordinate voting shares. Additional buybacks will be considered regularly in the context of market conditions.

06:00 EST HSBC sees RoTE of at least 12% for 2023 onwards - The bank said: "Our revenue outlook remains positive. Based on the current market consensus for global central bank rates, we expect net interest income of at least $36bn in 2023. While we continue to use a range of 30bps to 40bps of average loans for planning our ECL charge over the medium to long term, given current macroeconomic headwinds, we expect ECL charges to be around 40bps in 2023. We expect to manage the CET1 ratio within our medium-term target range of 14% to 14.5%. We intend to continue to manage capital efficiently, returning excess capital to shareholders where appropriate."

05:51 EST Faraday Future targets start of production date for FF 91 Futurist - Faraday Future announced it is targeting a start of production, or SOP, date for its flagship FF 91 Futurist of March 30, assuming timely receipt of funds from the company's investors, at the company's Hanford, California, manufacturing facility, "FF ieFactory California." The company expects the first vehicles built at its FF ieFactory California to be coming off the assembly line in early April, with deliveries to its first users before the end of April, assuming timely receipt of funds from the company's investors.

05:31 EST Rio Tinto, BMW announce new responsibly sourced aluminum partnership - Rio Tinto (RIO) and the BMW (BMWYY) announced a new partnership under which Rio Tinto plans to provide responsibly sourced aluminum to the BMW Group's vehicle production plant in Spartanburg, South Carolina, for use in body components from 2024. Low-carbon primary aluminium from Rio Tinto's hydro-powered operations in Canada, combined with recycled content, could generate a reduction of up to 70% in CO2 emissions compared to the BMW Group's benchmark for aluminum. The two companies have signed a memorandum of understanding, or MoU, which will see technical experts working together on how to embed these low-carbon solutions into the BMW Group's supply chain while ensuring the highest standards of vehicle quality are maintained. The partnership provides for the use of aluminum produced using Elysis on BMW production vehicles. Elysis is the world's first carbon free smelting technology for aluminum as it enables the production of aluminum metal without direct carbon dioxide emissions during the smelting process, instead emitting pure oxygen. Rio Tinto and the BMW Group will also work to deploy START from Rio Tinto. START provides supply chain traceability to customers and consumers with information about provenance and ESG standards.

05:23 EST Mainz Biomed to acquire ColoAlert IP portfolio from Uni Targeting Research - Mainz Biomed announced the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property, or IP, for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorectal cancer, or CRC, being commercialized across Europe. Simultaneously, the company also exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C., or SOCPRA, to outright purchase IP, including a pending patent, associated with a portfolio of novel gene expression, or mRNAm biomarkers that have demonstrated ability to detect CRC lesions, including advanced adenomas, or AA, a type of pre-cancerous polyp often attributed to this deadly disease. Mainz Biomed is commercializing ColoAlert across Europe and in select international markets through a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. Under the standard terms of all partnerships, Mainz Biomed is providing ColoAlert to the respective labs, including co-branding with key accounts, whereby each facility purchases Mainz Biomed's customized polymerase chain reaction, or PCR, assay kits on an on-demand basis and provides their respective network of physicians and patients with a comprehensive solution for advanced CRC detection. The company is in the process of evaluating the mRNA biomarkers it is has acquired from SOCPRA in ColoFuture and eAArly DETECT, an international multi-center clinical study assessing the potential for the integration of the mRNA biomarkers into ColoAlert. This particular portfolio of mRNA biomarkers selected by Mainz Biomed was based on work in the field by the University of Sherbrooke, where researchers tested multiple novel transcriptional biomarkers using colorectal cancer and precancerous lesion samples. The results from these studies demonstrated that the mRNA targets chosen by the Company provided a dynamic combination of sensitivity and specificity of detection. The ColoFuture study is evaluating the effectiveness of these biomarkers to enhance ColoAlert's technical profile to expand its capability to identify AA while increasing ColoAlert's rates of diagnostic sensitivity and specificity. ColoFuture's eAArly DETECT study is on track to complete enrollment in the first quarter of 2023, with results reported in the first half of 2023. Based on the study's outcome, Mainz Biomed will decide on integrating the biomarkers into the ReconAAsense study, which is on track to enroll patients in the summer of 2023, with results reported in 2025. The ReconAAsense study will form the basis of the data package for review by the FDA to achieve marketing authorization. It is a prospective clinical study that will include approximately 15,000 subjects from 150 sites across the United States. The study objectives include calculating sensitivity, specificity, positive predictive value, or PPV, and negative predictive value, or NPV, in average-risk subjects for CRC and AA. If successful, the company's mRNA and DNA-based CRC screening test will be positioned as the most robust and accurate at-home diagnostic screening test on the market, as it will not only detect cancerous polyps with a high degree of accuracy but has the potential to prevent CRC through early detection of precancerous adenomas.